



REC'D 09 SEP 2003
WIPO
PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.

The attached documents are exact copies of the international patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Den Haag, den
The Hague,
La Haye, le

16.07.2003

Der Präsident des Europäischen Patentamts
Im Auftrag
For the President of the European Patent Office
Le Président de l'Office européen des brevets
p.o.

Ulrike Staab

Patentanmeldung Nr.
Patent application no.
Demande de brevet n°

PCT/EP 03/03215

BEST AVAILABLE COPY

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation



Anmeldung Nr.: PCT/EP 03/03215

Application no.:
Demande n°:

Anmelder: 1. Biochemie Gesellschaft m.b.H - Kundl, Austria
Applicant(s): 2. ASCHER, Gerd - Kundl, Austria (US only)
Demandeur(s): 3: STAUFFER, Friedrich - Wien, Austria (US only)

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

TUBERCULOSIS TREATMENT

Anmeldetag: 27 March 2003 (27.03.2003)
Date of filing:
Date de dépôt:

In Anspruch genommene Priorität(en)
Priority(ies) claimed
Priorité(s) revendiquée(s)

Staat: Great Britain Tag: 28 March 2002 Aktenzeichen: 0207495.3
State: Date: (28.03.2002) File no.
Pays: Date: Numéro de dépôt:

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)
Designation of contracting states : See Form PCT/RO/101 (enclosed)
Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:
Remarks:
Remarques: Further applicants:

4. BERNER, Heinz - Wien, Austria (US only)
5. MANG, Rosemarie - Wien, Austria (US only)

Sheet No. ...3...

Box No. V DESIGNATION OF STATES

Mark the applicable check-boxes below; at least one must be marked.

The following designations are hereby made under Rule 4.9(a):

Regional Patent

- AP ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT (if other kind of protection or treatment desired, specify on dotted line)
- EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- EP European Patent: AT Austria, BE Belgium, BG Bulgaria, CH & LI Switzerland and Liechtenstein, CY Cyprus, CZ Czech Republic, DE Germany, DK Denmark, EE Estonia, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, SK Slovakia, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT SI Slovenia
- OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GQ Equatorial Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

RO/EP

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | | |
|---|--|---|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda | <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> OM Oman |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> PH Philippines |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> JP Japan | |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> KE Kenya | <input type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> KR Republic of Korea | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> BZ Belize | <input checked="" type="checkbox"/> KZ Kazakhstan | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> LC Saint Lucia | <input type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> CN China | <input type="checkbox"/> LR Liberia | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> CO Colombia | <input type="checkbox"/> LS Lesotho | <input checked="" type="checkbox"/> TN Tunisia |
| <input checked="" type="checkbox"/> CR Costa Rica | <input checked="" type="checkbox"/> LT Lithuania | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> LU Luxembourg | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> LV Latvia | |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> MA Morocco | <input type="checkbox"/> TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> MD Republic of Moldova | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> DM Dominica | | <input type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> DZ Algeria | <input type="checkbox"/> MG Madagascar | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> EC Ecuador | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia | |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> MN Mongolia | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> ES Spain | <input type="checkbox"/> MW Malawi | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> MX Mexico | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> MZ Mozambique | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> NO Norway | <input checked="" type="checkbox"/> ZM Zambia |
| <input checked="" type="checkbox"/> GE Georgia | | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> GH Ghana | | |

RO/EP

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

- VC Saint Vincent and the Grenadines
- SC Seychelles

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Tuberculosis Treatment

The present invention relates to tuberculosis treatment, such as treatment of diseases mediated by *Mycobacterium*, e.g. *Mycobacterium tuberculosis*, with pleuromutilins.


- 5 Tuberculosis is a chronic infectious disease mediated by infection with *Mycobacterium tuberculosis*. Tuberculosis is a major disease in developing countries, as well as an increasing problem in developed areas of the world. Although the infection may be asymptomatic for a considerable period of time, the disease is most commonly manifested as an acute inflammation of the lungs, resulting in fever and a nonproductive cough. If
- 10 untreated, serious complications and death typically result. Tuberculosis may be generally controlled by antibiotic therapy, such as by treatment with Isoniazid, see e.g. The Merck Index, 12th edition, item 5203; Rifampin (Rifampicin®), see e.g. The Merck Index, 12th edition, item 8382, Streptomycin, see e.g. The Merck Index, 12th edition, item 8983; but a major problem is the development of strain drug resistance against such antibiotics.
- 15 We have now found a compound class which shows surprisingly activity in the treatment of diseases caused by *Mycobacterium*, such as *Mycobacterium tuberculosis*, e.g. even against drug resistant strains.
- 20 In one aspect the present invention provides the use of a pleuromutilin in the preparation of a medicament for the treatment of diseaseses mediated by *Mycobacterium*.
- 25 In another aspect the present invention provides a method of treating diseases mediated by *Mycobacterium*, comprising administering to a subject in need of such treatment an effective, e.g. an anti-mycobacterium effective amount of a pleuromutilin.
- 30 *Mycobacterium* includes *M. tuberculosis*. Diseaseses mediated by *Mycobacterium* include mycobacterium infections. A pleuromutilin for treatment includes one or more pleuromutilins, e.g. a combination of different pleuromutilins. Treatment includes treatment and prophylaxis.
- 35 A pleuromutilin for use according to the present invention or for treating diseases according to the present invention is designated hereinafter as "a pleuromutilin(s) of (according to) the present invention".

A pleuromutilin of the present invention includes a pleuromutilin in the form of a free base, and, where existing, in the form of a salt, in the form of a solvate and in the form of a salt and a solvate, e.g. and in the form of a complex, such as a cyclodextrin complex.

A pleuromutilin of the present invention may exist in the form of isomers and mixtures

- 5 thereof, e.g. including diastereoisomers and mixtures thereof. Isomeric mixtures may be separated as appropriate, e.g. according to a method as conventional, to obtain pure isomers. The present invention includes a pleuromutilin according to the present invention in any isomeric form and in any isomeric mixture, such as described in patent literature cited below, which patent literature is introduced herein by reference with respect to isomeric forms of pleuromutins. Preferably the configuration in the mutilin ring is the same as in a naturally produced mutilin.
- 10


Pleuromutilin, a compound of formula



- 15
- is a naturally occurring antibiotic, e.g. produced by the basidiomycetes *Pleurotus mutilus* and *P.passeckerianus*, see e.g. The Merck Index, 12th edition, item 7694.


A number of further pleuromutilins having the principle ring structure of pleuromutilin and having e.g. antibacterial activity, have been developed.

- 20
- A pleuromutilin of the present invention includes a pleuromutilin having the basic structural elements as set out in formula




wherein R is vinyl or ethyl and the dotted line is a bond or is no bond.

The following numbering system is used in the present application:




The dotted line between positions 19 and 20 (and between positions 1 and 2) is a bond or is no bond. In a compound of formula A or of formula PLEU a hydrogen atom in positions 4, 7 and/or 8 of the ring system may be replaced by deuterium, and if the dotted line between positions 1 and 2 is no bond (single bond between positions 1 and 2) the ring system may be further substituted in positions 1 and/or 2, e.g. by halogen, deuterium or hydroxy. The group -O- in position 14 is further substituted, preferably by a substituted carbonyl group.

- 10 Examples of pleuromutilins according to the present invention includes e.g.
- A compound as disclosed in US3716579, e.g. of formula



wherein R is CH₃-(CH₂)₇-CH=CH-(CH₂)₇-COO-, CH₃-(CH₂)₄-CH=CH-CH₂-CH=CH-(CH₂)₇-COO-, CH₃-(CH₂)₉-CH=CH-(CH₂)₇-COO- or hydrogen;

- 15 - A compound as disclosed in GB1312148, e.g. of formula



wherein X, Y and Z are as defined in any one of the following groups:

- a. X is -CO-CH₂-R₁, wherein R₁ is H, Cl, Br, I, thiocyanato, azido, (N,N-tetramethylene-thiocarbamoyl)-mercapto, dithiocarbonic acid-O-(C₁₋₃)alkyl, -S-phenyl, S-phenyl


substituted by carboxyl or by one or two OH, -S-pyridyl, -S-benzyl, -S-(C₁₋₅)alkyl, or -S-(C₁₋₅)alkyl substituted by one or more amino, OH or carboxyl, Y is vinyl, and Z is H;

b. X is -CO-CO-OH, Y is vinyl and Z is H;

c. X is -COCH₃, Y is vinyl and Z is H;

5 d. X is COCH₂NH₂, Y is ethyl and Z is H;

e. X is a group of formula




-CO-C(=N)N, Y is ethyl and Z is H

f. X is H, Y is vinyl and Z is acetyl; or

g. X is COR₂, wherein R₂ is (C₁₋₅)alkyl, Y is vinyl and Z is H,


10 - A compound as disclosed in US4278674, e.g. of formula




wherein R₁ is vinyl or ethyl, n is an integer from 2 to 5, X is sulphur or a group -Y-phenylene-Z- or a group =NR₄, Y and Z are both sulphur or one of Y and Z is sulphur and the other is oxygen, R₄ is H or a second multilin ring of formula I-US4278674, wherein R₁ is as defined above and attached via a -O-CO-CH₂- group in position 14; each of R₂ and R₃ are (independently of each other) (C₁₋₁₀)alkyl, or R₂ and R₃ together with the nitrogen atom form pyrrolidino, piperidino, morpholino, thiomorpholino, or 1-hexahydro-1H-azepino, or R₂ and R₃ together with the nitrogen atom form piperazinyl, the second nitrogen atom of which is substituted by (C₁₋₅)alkyl, (C₁₋₄)hydroxyalkyl, (C₂₋₅)alkynoyloxy(C₁₋₄)alkyl, or benzoyloxy(C₁₋₄)alkyl, or

R₁ is as defined above, n = 2, R₃ is (C₁₋₁₀)alkyl, (C₁₋₄)hydroxyalkyl, (C₂₋₅)alkynoyloxy-(C₁₋₄)alkyl, or benzoyloxy(C₁₋₄)alkyl, X is =NR'₄ and R₂ together with R'₄ forms an ethylene bridge between both nitrogen atoms; such as


- 14-Desoxy-14[(2-diethylaminoethyl)mercaptoacetoxy]multilin, e.g. also known as tiaculin of formula



- A compound as disclosed in US4130709, e.g. of formula




- 5 wherein R is ethyl or vinyl, R₁ is selected from α- or β-anomers of hexopyranoses, hexofuranoses, pentopyranoses, pentofuranoses, pyranose and furanose aminosugars, disaccharides, trisaccharides and R₂ is H, benzoyl or (C₂₋₄)alkanoyl; or R₁ is 2-deoxy-2-(hydroxyimino)-3,4,6-tri-O-acetyl-α-D-glucopyranosyl or -galactopyranosyl, 2-deoxy-2-(hydroxyimino)-α-D-galactopyranosyl, 2-deoxy-2-amino-4,6-di-O-acetyl-α-D-glucopyranosyl, or 2-deoxy-2-acetamido-3,4,6-tri-O-acetyl-α-D-glucopyranosyl and R₂ is H;
- 10 -A compound as disclosed in US4129721; e.g. of formula




and the 19,20-dihydro derivative thereof and the tetra (C₂₋₆)alkanoyl derivatives thereof;

- A compound as disclosed in EP0013768, e.g. of formula




wherein R₁ is vinyl or ethyl, m is 0 or 1, and R₂ is a heterocyclic radical, in which a 5- or 6-membered, unsaturated or saturated heterocyclic ring containing one or more hetero atoms selected from O, S and N, is attached to the -S(CH₂)_m- group;

- 5 - A compound as disclosed in EP0153277, e.g. an N-acyl-14-O-[(1-amino-2-methylpropan-2-yl)thioacetyl]-mutilin or 19,20-dihydromutilin, such as of formula




wherein R₁ is vinyl or ethyl positions 19 and 20), and R₂ is optionally hydroxy-substituted aminoalkyl or a 5-membered saturated heterocycle, e.g. including Valnemulin (Econor®) of formula

10




- A compound as disclosed in US516526, e.g. of formula




wherein R₁ and R₂ independently of each other are H, alkyl, alkenyl, cycloalkyl, aryl or aralkyl;

- A compound as disclosed in WO9322288, e.g. of formula




- 5 wherein R₁ and R₂ are independently of each other H, alkyl, or, R₁ and R₂ together with the carbon atom to which they are attached are cycloalkyl; and R₃ and R₄ independently of each other are H, alkyl or substituted alkyl;

- A compound as disclosed in WO9725309, e.g. of formula



- 10 wherein Y is carbamoyloxy, wherein the N-atom is unsubstituted or mono- or disubstituted, such as a compound of formula



wherein R₁ is vinyl or ethyl, R₂ and R₃ independently of each other are H, or optionally substituted

- 15 - saturated or unsaturated (C₁₋₆) hydrocarbon or (C₃₋₆)cyclic hydrocarbon,
- heterocyclyl or aryl, or

R₂ and R₃ together form an optionally substituted cyclic group of 3 to 8 ring atoms, optionally containing one additional heteroatom selected from N, O and S, and optionally fused to a hydrocarbon ring, a heterocyclic group or an aromatic group; or

R₂ is one of the above monovalent groups and R₃ is a group selected from SO₂R₄, COR₅,

5 OR₅ and NR₆R₇; wherein

R₄ is optionally substituted,

- saturated or unsaturated (C₁₋₆)hydrocarbon or (C₃₋₈)cyclic hydrocarbon,

- heterocyclyl, aryl, (C₁₋₆)alkylamino or arylamino;

R₅ is optionally substituted

10 - saturated or unsaturated (C₁₋₆) hydrocarbon or (C₃₋₈)cyclic hydrocarbon,

- heterocyclyl or aryl,


R₆ and R₇ independently of each other are H, or optionally substituted

- saturated or unsaturated (C₁₋₆) hydrocarbon or (C₃₋₈)cyclic hydrocarbon,

- heterocyclyl or aryl, or

15 R₆ and R₇ together with the nitrogen atom to which they are attached form an optionally substituted (C₃₋₈)cyclic group, optionally containing one additional heteroatom selected from N, O or S, and optionally fused to a hydrocarbon ring, a heterocyclic ring or an aromatic group;

- A compound as disclosed in WO9805659, e.g. of formula




I-WO9805659

20


wherein R₁ is vinyl or ethyl, and R₂ is a group R₃, R₄CH₂-, or R₅R₆CH=CH-, wherein , each of R₃ and R₄ is an azabicyclic ring system, or R₅ and R₆ together with the carbon atom to which they are attached form an azabicyclic ring system;

- A compound of WO9821855; e.g. of formula





wherein n and m are independently of each other 0, 1 or 2; X is O, S, S(O), SO₂, -COO-, -NH-, -CONH-, -NHCONH-, or a bond; R₁ is vinyl or ethyl; R₂ is a non-aromatic monocyclic or bicyclic group containing one or two basic nitrogen atoms and attached through a ring carbon atom, e.g. R₂ is optionally substituted quinuclidinyl, azabicyclo[2.2.1]heptyl, azabicyclo[4.3.0]nonyl, azabicyclo[3.2.1]octyl, azabicyclo[3.3.0]octyl, azabicyclo[2.2.2]octyl, azabicyclo[3.2.1]octenyl, azabicyclo[3.3.1]nonyl or azabicyclo[4.4.0]decyl; R₃ is H, OH; or the moiety R₂(CH₂)_mX(CH₂)_nCH₂COO at position 14 of IA or IB is replaced by R_aR_bC=CHCOO, wherein one of R_a or R_b is hydrogen and the other is R₂; or R_a and R_b together form R₂;

- A compound as disclosed in WO0007974, e.g. a 14-acyloxy derivative of mutilin or 19,20-dihydromutilin having a 2-fluoro substituent, such as of formula




wherein R₁ is vinyl or ethyl (positions 19 and 20), and R₂COO- is acyloxy, e.g. HOCH₂CO₂- or R-X-CH₂CO₂, wherein X is O, S or NR' and R and R' are independently of each other an aliphatic or aromatic group, preferably R₂COO- is a carbamoyl group, such as a group R₃R₄NCO₂- wherein R₃ and R₄ have various meanings (e.g. R₃ and R₄ have the meaning as disclosed for the meaning of R₂ and R₃ in WO9725309);

- A compound as disclosed in WO0027790, e.g. a compound of formula





wherein R₁ is a R^A(CH₂)_nO(CH₂)_m, R^A(CH₂)_p, or a group of formula





5 wherein R is a spiro-fused mono- or bicyclic ring containing one or two
basic N-atoms; X₁ and X₂ which may be the same or different, are each -CH₂- or -C=O-,
provided that at least one of X₁ and X₂ is -C=O; and Y is -NH-, -CH₂- or -CH₂-CH₂;
R^A is an optionally substituted aryl group or heteroaryl group linked via a carbon atom;
e.g. R^A is optionally substituted phenyl, thiophenyl, pyridinyl, furyl, thiazolyl, isoxazolyl,
benzimidazolyl, quinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl or benzthiazolyl:
m is 1, 2 or 3; n is 0, 1 or 2; p is 1 to 4; R₂ is vinyl or ethyl; and R₃ is H, OH or F, and R₄ is
10 H; or R₃ is H and R₄ is F;

- A compound as disclosed in WO0037074, e.g. a compound of formula





wherein R₁ is an optionally substituted heteroaryl group which comprises a 5-membered
heteroaromatic ring which has at least one N-atom, e.g. a pyrrole, pyrazole, imidazole,
15 1,2,3-triazole, 1,2,4-triazole, indole, benzimidazole, benzotriazole, 2-aza-indole or 6-aza-
indole; and which is linked via a N-atom; R₂ is vinyl or ethyl; R₃ is H, OH or F, and R₄ is H;
or R₃ is H and R₄ is F;

- A compound as disclosed in WO0073287, e.g. a compound of formula



wherein R_1 is optionally substituted aryl, e.g. azabicyclo-octyl; or an optionally substituted nitrogen containing ring, e.g. piperidinyl; R_2 is vinyl or ethyl; R_3 is H, OH or F and R_4 is H; or R_3 is H and R_4 is F;

- 5 - A compound as disclosed in WO0114310, e.g. a compound of formula




wherein R_1 is a nitrogen containing heterocycle, an optionally substituted aryl or optionally substituted heteroaryl, or CH_2R_5 ,

- e.g. R_1 is optionally substituted phenyl, 3-pyridyl, 4-pyridyl, pyrimidin-2-yl, 1,3,4-thiadiazol-2-yl, benzothiazol-2-yl, 2H-1,2,4-triazol-3-yl, azabicycloheptyl, azabicyclooctyl or piperidinyl;
10 R_2 is vinyl or ethyl; R_3 is H, OH or F and R_4 is H; or R_3 is H and R_4 is F; R_5 is halogen or SR_6 ; and R_6 is aminoalkyl, a nitrogen containing heterocycle, or an optionally substituted aryl or optionally substituted heteroaryl; e.g. R_6 is optionally substituted phenyl, 3-pyridyl, 4-pyridyl, pyrimidin-2-yl, 1,3,4-thiadiazol-2-yl, benzothiazol-2-yl, 2H-1,2,4-triazol-3-yl, azabicycloheptyl, azabicyclooctyl or piperidinyl;
15

- azabicycloheptyl, azabicyclooctyl or piperidinyl;

- A compound as disclosed in WO0109095, e.g. a compound of formula



wherein R is hydrogen or alkyl; R_1 is hydrogen or a group of formula




wherein X is S, O, or NR₁₀, wherein R₁₀ is H or alkyl, or N⁺(R'₁₀)₂ wherein R'₁₀ is alkyl in the presence of an appropriate anion; and R₉ is amino, alkyl, aryl, heterocycl or mercapto; and, if X is oxygen, R₉ is additionally hydrogen; R₂ is arylene, e.g. phenylene; or heterocyclene; R₄ is hydrogen or alkyl; R₅ is hydrogen or alkyl; R₃, R_{3'}, R₆, R₇ and R₈


- 5 independently of each other are hydrogen or deuterium; or R and R₂ together with the nitrogen atom to which they are attached form non-aromatic heterocyclene and R₁ is a group of formula



wherein X and R₉ are as defined above; e.g. a compound of formula




- 10 wherein R_{1s} is hydrogen or a group of formula



wherein R_{6s} is hydrogen or deuterium; R_{2s} is hydrogen, methyl or tert-butyl; R_{7s} is hydrogen or methyl; and R_{3s}, R_{4s} and R_{5s} are hydrogen or deuterium;


- A compound as disclosed in WO0174788, e.g. a compound of formula




- 15 wherein R₁ is a 5- or 6-membered optionally substituted heteroaryl group;

e.g. pyridine, pyridazine, pyrimidine, pyrazine, isoxazole, thiazole, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, benzimidazole, 3-oxo-3,4-dihdropyrido[2,3-b]pyrazine, or pyrazolo[1,5-a]pyrimidine; and R₂ is vinyl or ethyl;


- A compound as disclosed in WO0204414, e.g. a compound selected from 14-O-
5 [(cycloalkyl-sulfanyl)acetyl]mutilins; 14-O-[(cycloalkyl-alkyl-sulfanyl)acetyl] mutilins; 14-O-[(cycloalkoxy)acetyl]mutilins; or 14-O-[(cycloalkyl-alkoxy)acetyl] mutilins, such as of formula



wherein R is hydrogen; R₁ is hydrogen or a group of formula




- 10 wherein X is sulphur, oxygen or NR₁₀, wherein R₁₀ is hydrogen or alkyl; and R₉ is
amino, alkyl, aryl or heterocyclyl; and, if X is oxygen, R₉ is additionally hydrogen; Y is
sulphur or oxygen; R₂ is hydrogen or one or more substituents, R₄ is hydrogen or alkyl; R₅ is
hydrogen or alkyl; R₃ and R_{3'} are hydrogen, deuterium, or halogen; R₆, R₇ and R₈ are
hydrogen or deuterium; m is a number selected from 0 to 4; n is a number selected from 0
to 10; and p is a number selected from 0 to 10; with the proviso that n plus p are at least 1;
15 e.g. a compound of formula




I_p-WO204414

wherein R_{1p} is hydrogen or the residue of an amino acid;

- A compound as disclosed in WO0212199, e.g. a compound of formula



IA-WO0212199




IB-WO0212199

wherein R_1 is:

- a 5- or 6-membered aromatic or heteroaromatic ring attached via a ring carbon atom, preferably pyridyl, and comprising a substituent selected from halo, $\text{R}_7\text{O}-$, $\text{R}_7\text{S}-$ or $\text{R}_8\text{R}_9\text{N}-$ on a ring carbon adjacent to the carbon of attachment; or
- a 5- or 6-membered dihydro heteroaromatic ring attached via a ring carbon atom and comprising one oxygen or one or two nitrogen atoms and optionally fused to phenyl, a 5- or 6-membered heteroaryl ring comprising one or two nitrogen atoms or a 5- or 6-membered heterocyclil ring comprising a sulphur, oxygen or nitrogen atom and further comprising a substituent selected from oxo or thioxo on a ring carbon adjacent to the carbon of attachment;
- a 6-membered tetrahydro heteroaromatic ring attached via a ring carbon atom comprising one or two nitrogen atoms and further comprising two substituents independently selected from oxo or thioxo wherein one of the substituents is on a ring carbon adjacent to the carbon of attachment; or
- a bicyclic heteroyaryl ring attached via a ring carbon atom and comprising nine or ten ring atoms and from one to four nitrogen atoms;

wherein the ring of R_1 may be optionally further substituted; R_2 is vinyl or ethyl; R_3 is H, OH or F and R_4 is H, or R_3 is H and R_4 is F; and R_5 and R_6 together form an oxo group; or R_3 and R_4 is each H and R_5 is H, or OH and R_6 is H, or R_5 is H and R_6 is H or OH; R_7 is optionally substituted (C_{1-6})alkyl; and R_8 and R_9 are independently selected from hydrogen or optionally substituted (C_{1-6})alkyl.


- A compound as disclosed in WO0222580, of formula



wherein R and R₂ together with the nitrogen atom to which they are attached form pyrrolidinyl or piperidinyl, R₁ is a group of formula




- 5 hydrogen or alkyl, R₆, R₇ and R₈ are hydrogen or deuterium; R₉ is amino, alkyl, aryl, heterocyclyl or mercapto; and, if X is oxygen, R₉ is additionally hydrogen; R₁₀ is hydrogen or alkyl, R'₁₀ is alkyl, X is sulphur, oxygen, NR₁₀, or N⁺(R'₁₀)₂ in the presence of an appropriate anion, Y is sulphur or oxygen, and m is 0, 1 or 2;
- 10 with the proviso that, when R and R₂ together with the nitrogen atom to which they are attached form piperidinyl, m is 0, Y is S and Y is attached in position 3 of said piperidine ring that group of formula I which is attached to the piperidine ring via the residue Y is either in the (S)-configuration or in the (R)-configuration, preferably in the (S)-configuration; preferably a compound of formula



- 15 wherein R_{3p}, R'_{3p}, R_{6p}, R_{7p} and R_{8p} are, index-number correspondingly, as defined for a compound of formula I-WO0222580 for R₃, R'₃, R₆, R₇ and R₈; and R_{5p} is hydrogen or one or more substituents, and if the group attached to the piperidine ring via the sulphur atom is in position 3 of said piperidine ring and R_{5p} is hydrogen, then the group attached to the sulphur atom is either in the (S)-configuration or in the (R)-configuration;


a compound of formula



I_q-WO0222580


wherein R_{3q}, R'_{3q}, R_{6q}, R_{7q} and R_{8q} are, index-number correspondingly, as defined for a compound of formula I-WO0222580 for R₃, R'₃, R₆, R₇ and R₈; R_{5q} is hydrogen or one or more substituents, preferably hydrogen; and R_q is that part of an amino acid which remains if the carboxylic group is split off;

5 a compound of formula



I_r-WO0222580

wherein R_{3r}, R'_{3r}, R_{4r}, R_{6r}, R_{7r} and R_{8r} are, index-number correspondingly, as defined for a compound of formula WO0222580 for R₃, R'₃, R₄, R₆, R₇ and R₈; R_{5r} is hydrogen or one or more substituents, and R_{1r} is that part of an amino acid which remains if the carboxylic group is split off, or a compound of formula




15 wherein R_{3s}, R'_{3s}, R_{4s}, R_{6s}, R_{7s} and R_{8s}, respectively, are, index-number correspondingly, as defined for a compound of formula I-WO0222580 for R₃, R'₃, R₄, R₆, R₇ and R₈;

R_{5s} is hydrogen or one or more substituents, preferably hydrogen; and R_{1s} is that part of an amino acid which remains if the carboxylic group is split off; e.g. wherein in a compound of formula I_s the group attached to the piperidine ring via the sulphur atom is either in the (S)-configuration or in the (R)-configuration; e.g. wherein in a group R_{1s} the amine group of the amino acid residue is either in the (S)-configuration or in the (R)-configuration.

- 5 amino acid residue is either in the (S)-configuration or in the (R)-configuration.

Furthermore we have found novel pleuromutilins which show antibacterial activity and activity against *Mycobacterium tuberculosis*.

- 10 In another aspect the present invention provides a pleuromutilin, which is selected from the group consisting of compounds of formulae




wherein R_{EX} is as set out in TABLE 1. In all Examples of TABLE 1 the compounds are of formula I_{EX}, with the exception of Example 12 in which the compound is of formula I'-_{EX} - H^1 -H-

- 15 NMR-data of the compounds described and obtained according, e.g. analogously, to a method as described in the examples, are also indicated in TABLE 1:

TABLE 1

R_{EX} 	Example 1 14-O-[4-Amino-cyclohexan-1-yl-sulfanyl)-acetyl]-mutilin in the form of a hydrochloride $(d_6\text{-DMSO}): 7.9$ (b,3H,NH ₃), AB-system ($\nu_A = 3.23$, $\nu_B = 3.29$, 2H, H ₂₂ , J=15.2Hz),3.03(m,1H,SCH), 3.10(m,1H,CHN)
R_{EX} 	Example 2 14-O-[(2-(R*)-((R)-Histidinyl)-amino-cyclohexan-1-(S*)-yl)-sulfanyl acetyl]-mutilin in the form of a hydrochloride $(d_6\text{-DMSO}): \text{Diastereoisomers: } 8.4, 9.0$ (2xm,2H,NH), 7.5,8.7 (2xb,2H,imidazole),6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.52 (d,1H,J=5.2Hz,H ₁₄),4.2(m,1H,a-H-histidine) 3.45(m,1H,H ₁₁), 3.3(m,2H,H ₂₂), 2.7 (m,1H,CHS), 1.18,1.45 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz)

R_{EX}



Example 3a

14-O-[(2-(R*)-Methylamino-cyclohexan-1-(S*)-yl)-sulfanyl acetyl]-mutilin


(d₆-DMSO): Diastereoisomers: 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5,2Hz,H₁₄), 4.50 (d,1H,OH,J=5Hz), 3.45(t,1H,H₁₁,J=5Hz), 3.25(m,2H,H₂₂), 3.25 (m,1H,CHN), 2.82 (m,1H,CHS), 2.38 (d,3H,CH₃NH, J=5.1Hz), 1.3,1.34) 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).

Example 3b

14-O-[(2-(R*)-Methylamino-cyclohexan-1-(R*)-yl)-sulfanyl acetyl]-mutilin

(d₆-DMSO): Diastereoisomers: 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5,2Hz,H₁₄), 4.50 (d,1H,OH,J=5Hz), 3.45(t,1H,H₁₁,J=5Hz), 3.25(m,2H,H₂₂), 3.25 (m,1H,CHN), 2.65 (m,1H,CHS), 2.43 (d,3H,CH₃NH, J=5.1Hz), 1.3,1.34) 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

R_{EX}




Example 4

(14-O-[4-((R)-Valyl-amino-cyclohexane-1-yl)-sulfanyl]-acetyl]-mutilin in the form of a hydrochloride

(CD₃OD): 8.3(d,1H,NH), 8.1(b,3H,NH₃⁺), 6.15(m,1H,H₁₉), 5.55(d,1H, H₁₄), 5.05(m,2H,H₂₀), 3.75(m,1H, NCHCO), 3.3(m,1H, NCH), 3.42(d, 1H,H₁₁), 3.25(m,2H,SCH₂CO), 2.98 (m,1HCHS), 0.9 (d,6H,(CH₃)₂CH), 1.08,1.36(2xs,6H,(CH₃)₁₈,(CH₃)₁₅), 0.65,0.83(2xd, 6H, (CH₃)₁₆,(CH₃)₁₇)

R_{EX}



Example 5a

14-O-[(3-(R*)-Amino-cycloheptan-1(R*)-yl)sulfanyl]acetyl]-mutilin and 14-O-[(3-(S*)-amino-cycloheptan-1(S*)-yl)-sulfanyl]-acetyl]mutilin in the form of a hydrochloride (diastereoisomeric mixture)


(d₆-DMSO): 8.0 (b,3H,NH₃⁺), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5,2Hz,H₁₄), 3.1,3.2 (2xm1H, CHNH₃⁺), 3.4(m, 1H,H₁₁,), 3.3 (m,2H,H₂₂), 2.9 (m,1H,SCH), 1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.9 (m,6H,CH(CH₃)₂), 0.75,0.88 (2xd, (CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

Example 5b

14-O-[(3-(R*)-Amino-cycloheptan-1(S*)-yl)sulfanyl]acetyl]-mutilin and 14-O-[(3-(S*)-Amino-cycloheptan-1(R*)-yl)sulfanyl]acetyl]-mutilin in the form of a hydrochloride (diastereoisomeric mixture)

(d₆-DMSO): 7.8(b,3H,NH₃⁺), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d, 1H,J=5,2Hz,H₁₄), 3.15(2xm1H, CHNH₃⁺), 3.4(m,1H,H₁₁,), 3.3 (m,2H,H₂₂), 2.95 (m,1H,SCH), 1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.9 (m,6H,CH(CH₃)₂), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)






R_{EX}




Example 6

14-O-[(3-(R/S)-(R)-Valylamino-1-(R/S)-yl)sulfanyl]acetyl]mutilin in the form of a hydrochloride

(d₆-DMSO): 8.4(m,1H,NHC=O), 8.1(b,3H, NH₃⁺), 6.15, 5.1 (2xm, H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5,2Hz,H₁₄), 3.5,3.9 (2xm,1H, a-H-valyl), 3.15(2xm1H, CHNH₃⁺), 3.4(m,1H,H₁₁,), 3.3 (m,2H,H₂₂), 2.95 (m,1H,SCH), 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.9 (m,6H, CH(CH₃)₂), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

R_{EX} 	Example 8a 14-O-[3-(R*)-((R)-Valyl-amino-cyclopentan-1-(S*)-yl)-sulfanyl]-acetyl]mutilin in the form of a hydrochloride (DMSO-d ₆): 8.5 (d, 1H, NH,J=7.2Hz), 8.1 (bs, 3H, NH ₃ ⁺), 6.15,5.06, 5.02 (3xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.55 (d,1H,H ₁₄ ,J=8.2Hz), 4.05 (m,1H,H-alpha-valyl), 3.15 (m,1H,H-1'), 3.2-3.5 (m,H-3',H ₁₁ ,H ₂₂), 1.35,1.05 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.91, 0.88 (d, (CH ₃) ₂ CH,J=6.8Hz), 0.8,0.62 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=6.8Hz)
R_{EX} 	Example 8b 14-O-[3-(S*)-((R)-Valyl-amino-cyclopentan-1-(R*)-yl)-sulfanyl]-acetyl]mutilin in the form of a hydrochloride (DMSO-d ₆): 8.5 (d, 1H, NH,J=7.2Hz), 8.1 (bs, 3H, NH ₃ ⁺), 6.15,5.06,5.02 (3xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.55 (d,1H,H ₁₄ ,J=8.2Hz), 4.05 (m,1H,H□-valyl), 3.15 (m,1H,H-1'), 3.2-3.5 (m, H3',H ₁₁ ,H ₂₂), 1.35,1.05 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.91, 0.89 (d, (CH ₃) ₂ CH,J=6.9Hz), 0.8,0.62 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=6.8Hz).
R_{EX} 	Example 8c 14-O-[3-(S*)-((R)-Valyl-amino-cyclopentan-1-(S*)-yl)-sulfanyl]-acetyl]mutilin and 14-O-[3-(R*)-((R)-valyl-amino-cyclopentan-1-(R*)-yl)-sulfanyl]-acetyl]mutilin in the form of a hydrochloride (mixture of trans-diastereoisomers) (DMSO-d ₆): 8.52,8.53 (2xd, 1H, NH,J=6.9Hz), 8.1 (bs, 3H, NH ₃ ⁺), 6.15,6.12,5.0-5.1 (6xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.54,5.55 (2xd,1H,H ₁₄ , J=8.2Hz), 4.15 (m,1H,H□-valyl), 3.1-3.5 (m, H-1',H3',H ₁₁ ,H ₂₂), 1.35,1.05 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.91, 0.88 (d, (CH ₃) ₂ CH,J=6.8Hz), 0.8,0.62 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=6.8Hz)
R_{EX} 	Example 9 14-O-[(3-(R/S)-Amino-cyclopentyl)-sulfanyl]-acetyl]mutilin-hydrochloride (DMSO-d ₆): 8.03 (bs, 3H, NH ₃ ⁺), 6.13,5.05 (2xm,3H,H ₁₉ ,H ₂₀ ,H ₂₁), 5.55 (d,1H,H ₁₄ ,J=8.0Hz), 3.2-3.6 (m,H-3',H ₁₁ ,H ₂₂), 3.14 (m,1H,H-1'), 1.35,1.05 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.8,0.62 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=6.8Hz)
R_{EX} 	Example 10 14-O-[(2-(R*)-((R)-Valyl)-methylamino-cyclohexan-1-(R*)-yl)-sulfanyl acetyl]mutilin in the form of a hydrochloride (d ₆ -DMSO): Diastereoisomers: 8.0(m,3H.NH ₃ ⁺), 6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.52 (d,1H,J=5.2Hz,H ₁₄), 4.50 (m,1H,OH),4.2 (m,1H,a-H-valine),3.45(m,1H,H ₁₁),3.25(m,2H,H ₂₂),3.25,(m,1H, CHN), 2.82 (m, 1H,CHS), 2.88,2.94 (2xs,3H,CH ₃ N),1.3,1.34),1.18,1.45


	(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88, (2xd,(CH ₃) ₁₆ , (CH ₃) ₁₇ ,J=5.4Hz)
R _{EX}	Example 11 14-O-[(3-Guanidino-phenylsulfanyl)-acetyl]mutilin in the form of a hydrochloride (CDCl ₃): 0.58(d, 3H, H ₁₆ , J=7.2Hz), 0.81 (d, 3H, H ₁₇ , J=7.3Hz), 1.02 (s, 3H, H ₁₈), 1.32 (s, 3H, H ₁₅), ABX-system(ν_A = 1.2, ν_B = 1.88, H _{13a} , H _{13b} , J=16.1Hz, J=9.1Hz), 2.08(d,1H, H ₄ , J=2.1Hz), ABXY-system(ν_A = 2.23, ν_B = 2.19, H _{2a} ,H _{2b} , J=16.2Hz, J=9.1Hz, J=1.8Hz), 2.3(m,1H,H ₁₀), 3.4 (d,1H,H ₁₁ , J=5.98Hz), AB-system(ν_A = 3.81, ν_B = 3.89, 2H, H ₂₂ , J=14.1Hz), 5.18(dd,1H, H _{20a} , J=17.5Hz, J=1.6Hz), 5.29(dd,1H, H _{20b} , J=11Hz, J=1.6Hz), 5.51 (d,1H, H ₁₄ , J=8.3Hz), 6.05 (dd,1H,H ₁₉ ,J=11Hz, J=17.5Hz), 7.0 (m,1H, arom.H), 7.18 (m2H, arom.H), 7.3t,1H, arom.H ₅ , J=8Hz
R _{EX}	Example 12 14-O-[(N-(3-Methyl-2(R)-amino-butryryl)-piperidine-3(S)-yl)-sulfanyl acetyl]-2(S)-fluoro-mutilin in he form of a hydrochloride (DMSO-d ₆): Rotamers: 7.95 (bs, 3H, NH ₃ ⁺), 6.12,5.05 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.56,5.52 (2xd,1H,H ₁₄ ,J=8.3Hz), 4.92 (ddd,1H, H ₂ ,J=51.3,8.4,8.0Hz), 4.7,4.69 (2xd,1H,11-OH,J=6.1Hz), 4.06 (m,1H,H ₂ -valyl), 4.3,4.25,3.91,3.88,2.6-3.6 (m, 4xCH ₂ N,SCH,H ₁₁ ,H ₂₂), 1.39,1.06 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.99,0.9,0.84,0.64 (4xd, (CH ₃) ₂ CH,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=6.8Hz)
R _{EX}	Example 13 14-O-[((Piperidin-3(S)-yl)methyl-sulfanyl)-acetyl]-mutilin in the form of a hydrochloride (d ₆ -DMSO,350K): 6.15, 5.05 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.55 (d, 1H,5.2Hz, H ₁₄), 3.4 (d,1H,H ₁₁ ,J=5.2Hz), 3.05, 2.95,2.52, 2.31,2.09, (5xm,4H, CH ₂ NCH ₂), 3.2 (m,2H,SCH ₂ C=O), 2.48 (m,2H,CHCH ₂ S), 1.18,1.45 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈),0.75,0.88,(2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ , J=5.4Hz)
R _{EX}	Example 14 14-O-[((Azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the form of a hydrochloride 400mg of 14-O-[((N-BOC-azepan-4-(R/S)-yl)-sulfanyl acetyl)-mutilin (d ₆ -DMSO): 8.2-8.5 (b,2H,NH ₂ ⁺),6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.52(d,1H,J=5.2Hz,H ₁₄), 4.52 (d,1H,OH,J=6.2Hz)3.4(t,1H,H ₁₁ ,J=6.2Hz), 3.3 (m,2H,H ₂₂), 2.9-3.2 (2xm,3H,SCH, CHNCH), 1.18,1.45 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz)
R _{EX}	Example 15 14-O-[((N-(R)-Valyl-azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin-hydrochloride (d ₆ -DMSO): 7.7-8.0 (b,3H,NH ₃ ⁺),6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁),5.52(d, 1H,J=5.2Hz,H ₁₄), 4.52 (d,1H,OH,J=6.2Hz), 3.4(t,1H, H ₁₁ ,J=6.2Hz), 4.1(m, α -H-valine), 3.4,2.6(2xm,4H,CH ₂ NCH ₂)3.3 (m,2H,H ₂₂), 2.9 (m,1H,SCH), 1.18,1.45 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88 (2xd,(CH ₃) ₁₆ , (CH ₃) ₁₇ ,J=5.4Hz)



Example 16

14-O-[(N-(R)-Valyl-pyrrolidin-3(S)-yl)-sulfanyl-acetyl]-mutilin-hydrochloride

(CD₃OD): Rotamer, 8.1(b,3H,NH3), 6.3-6.4(m,1H,H19), 5.75(d,1H, H14), 5.15(m,2H,H20), 4.15(m,1H, NCHCO), 3.9(m,1H,NCH),3.6 (m, 1H,NCH),3.42(d,1H,H11), 3.28-3.35(m,2H,SCH₂CO), 0.95,0.98 (2xd, 6H,(CH₃)₂CH), 1.08,1.36(2xs,6H,(CH₃)₁₈, (CH₃)₁₅), 0.65,0.83 (2xd,6H, (CH₃)₁₆, (CH₃)₁₇)




Example 17

14-O-[(N-(R)-Piperoyl-piperidin-4-yl)methyl-sulfanyl]-acetyl]-mutilin in the form of a hydrochloride

¹H-NMR(d₆-DMSO,350K): 6.15, 5.05 (2xm,H₁₉,H₂₀,H₂₁), 5.55 (d,1H,5,2Hz,H₁₄), 3.35 (d,1H,H₁₁,J=5.2Hz), 4.3 (m, α -H-piperol), 4.2, 4.05, 3.75 (4xm,CH₂NCH₂), AB-system: 3.12,3.18, J=14.7Hz,H₂₂), 2.8 (m,1H,SCH), 1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

In another aspect the present invention provides a compound of formula



5 wherein

- the dotted line is a bond (double bond between positions a=b), R_{1A} is hydrogen and R_{2A} is not present,

or

- the dotted line is no bond (single bond between positions a-b) and R_{1A} and R_{2A}

10 independently of each other are hydrogen, halogen or deuterium,

R_{3A} is (C₁₋₆)alkyl,

R_{4A} is hydrogen, (C₁₋₆)alkyl, a group -C(=NH)-NH₂, or the residue of an amino acid,

R_{5A} is hydrogen, or


R_{4A} and R_{5A} together are a group =CH-NH₂,

15 R_{6A} is hydrogen or deuterium, and

m_A is 0, 1, 2, 3, 4, or 5.

In a compound of formula IA preferably






- the dotted line is no bond;
 - R_{1A} is hydrogen,
 - 5 - R_{2A} is hydrogen,
 - R_{3A} is (C_{1-4})alkyl, such as methyl,
 - R_{4A} and R_{5A} are as defined above,
 - R_{6A} is hydrogen, and
 - m_A is 2, 3 or 4;
- 10 e.g. including pleuromutilins, which are selected from the group consisting of compounds of formula



wherein R_{EX} is as set out in TABLE 2. 1H -NMR-data of the compounds described and obtained according, e.g. analogously, to a process as described in the examples are also indicated in TABLE 2:

TABLE 2


R_{EX}	Example 18
	<p>Example 18a 14-O-[(3-(R^*)-Amino-1-methyl-cyclopentan-1-(R^*)-yl)-sulfanyl]-acetyl]-mutilin and 14-O-[(3-(S^*)-amino-1-methyl-cyclopentan-1-(S^*)-yl)-sulfanyl]-acetyl]-mutilin in the form of a hydrochloride (mixture of trans-diastereoisomers) (DMSO-d₆): 7.98 (bs, 3H, NH₃⁺), 6.13, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.2Hz), 3.56 (m, 1H, H-3'), 3.3-3.3 (m, H₁₁, H₂₂), 1.36, 1.30, 1.29, 1.05 (4xs, 9H, CH₃CS, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.9Hz)</p>

 <p>R_{EX}</p>	<p>Example 18b 14-O-[(3-(R*)-Amino-1-methyl-cyclopentan-1-(S*)-yl)-sulfanyl]-acetyl]-mutilin and 14-O-[(3-(S*)-Amino-1-methyl-cyclopentan-1-(R*)-yl)-sulfanyl]-acetyl]-mutilin in the form of a hydrochloride (mixture of cis-diastereoisomers) (DMSO-d₆): 8.03 (bs, 3H, NH₃⁺), 6.13, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.53 (d, 1H, H₁₄, J=8.0Hz), 4.52 (bs, 1H-11-OH), 3.51 (m, 1H, H-3'), 3.2-3.4 (m, H₁₁, H₂₂), 1.41, 1.40, 1.35, 1.05 (4xs, 9H, CH₃CS(CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.9Hz)</p>
 <p>R_{EX}</p>	<p>Example 19</p>
 <p>R_{EX}</p>	<p>Example 19a 14-O-[(1S*,3S*)-3-((R)-2-Amino-3-methyl-butyrylaminio)-1-methyl-cyclopentylsulfanyl]-acetyl]-mutilin in the form of a hydrochloride Rotamer 1: (DMSO-d₆): 8.48 (d, 1H, NH, J=7.1Hz), 8.1 (bs, 3H, NH₃⁺), 6.11, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.5Hz), 4.15 (m, 1H, H-3'-valyl), 3.1-3.5 (m, H-1', H-3', H₁₁, H₂₂), 1.35, 1.32, 1.05 (3xs, CH₃CS(CH₃)₁₅, (CH₃)₁₈), 0.91, 0.88 (d, (CH₃)₂CH, J=6.8Hz), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz). Rotamer 2: (DMSO-d₆): 8.48 (d, 1H, NH, J=7.1Hz), 8.1 (bs, 3H, NH₃⁺), 6.11, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.5Hz), 4.5 (bs, 1H, 11-OH), 4.15 (m, 1H, H-3'-valyl), 3.1-3.5 (m, H-1', H-3', H₁₁, H₂₂), 1.35, 1.32, 1.05 (3xs, CH₃CS(CH₃)₁₅, (CH₃)₁₈), 0.91, 0.88 (d, (CH₃)₂CH, J=6.8Hz), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)</p>
 <p>R_{EX}</p>	<p>Example 19b 14-O-[(1R*,3R*)-3-((R)-2-Amino-3-methyl-butyrylaminio)-1-methyl-cyclopentylsulfanyl]-acetyl]-mutilin-hydrochloride (DMSO-d₆): Rotamers: 8.53 (d, 1H, NH, J=7.2Hz), 8.1 (bs, 3H, NH₃⁺), 6.12, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.4Hz), 4.52 (d, 1H, 11-OH, J=6.1Hz), 4.25 (m, 1H, H-3'-valyl), 3.2-3.5 (m, H-1', H-3', H₁₁, H₂₂), 1.42, 1.39, 1.35, 1.05 (4xs, 9H, CH₃CS(CH₃)₁₅, (CH₃)₁₈), 0.91, 0.88 (d, (CH₃)₂CH, J=6.8Hz), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)</p>
 <p>R_{EX}</p>	<p>Example 19c 14-O-[(1R*,3S*)-3-((R)-2-Amino-3-methyl-butyrylaminio)-1-methyl-cyclopentylsulfanyl]-acetyl]-mutilin and 14-O-[(1S*,3R*)-3-((R)-2-Amino-3-methyl-butyrylaminio)-1-methyl-cyclopentylsulfanyl]-acetyl]-mutilin in the form of a hydrochloride (mixture of cis-diastereoisomers) (DMSO-d₆): 8.4, 8.3 (2xd, 1H, NH, J=7.2Hz), 8.17 (bs, 3H, NH₃⁺), 6.12, 5.06, 5.02 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.3Hz), 4.53</p>

	(bs,1H,11-OH), 4.15 (m,1H,H ₂ -valyl), 3.2-3.5 (m, H-1',H-3',H ₁₁ , H ₂₂), 1.36,1.35,1.32,1.05 (4xs,9H,CH ₃ CS,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.92, 0.91,0.89,0.88 (2xd,6H,(CH ₃) ₂ CH,J=6.8Hz), 0.8,0.62 (2xd, (CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=6.8Hz)
R _{EX}	Example 20 14-O-[(3-(R/S)-Amino-cyclohexan-1-(R/S)-methyl-1-yl)sulfanyl]acetyl]mutilin in the form of a hydrochloride (d ₆ -DMSO): Rotamers: 7.90(b,3H,NH ₃ ⁺), 6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ , H ₂₁), 5.52(d,1H,J=5,2Hz,H ₁₄), 4.5 (2xd,1H,OH,J=6Hz), 3.4(t,1H, H ₁₁ ,J=6Hz), 3.3 (m,2H,H ₂₂), 3.1(m,1H,NCH), 1.2,1.25 (2xs,3H, CH ₃ CS)-1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.9 (m,6H,CH(CH ₃) ₂), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz)
R _{EX}	Example 21a 14-O-[(3-(R*)-Guanidino-cyclohexan-1-(R*)-methyl-1-yl)-acetyl]mutilin in the form of a hydrochloride + 14-O-[(3-(S*)-Guanidino-cyclohexan-1-(S*)-methyl-1-yl)-acetyl]mutilin in the form of a hydrochloride (d ₆ -DMSO): 10.7,8.6,7.65,(3xm,2H,NH),6.7-7.5(b,2HNH), 6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.52(d,1H,J=5,2Hz,H ₁₄), 5.5 (d,1H,OH,J=6Hz), 3.9,3.6(2x,m1H, CHNH), 3.4(t,1H,H ₁₁ ,J=6Hz), 3.3 (m,2H,H ₂₂), 1.4,1.45(2xs,3H,CH ₃ CS), 1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz).
R _{EX}	Example 21b 14-O-[(3-(R*)-Guanidino-cyclohexan-1-(S*)-methyl-1-yl)-acetyl]mutilin in the form of a hydrochloride + 14-O-[(3-(S*)-Guanidino-cyclohexan-1-(R*)-methyl-1-yl)-acetyl]mutilin in the form of a hydrochloride (d ₆ -DMSO): 10.7,8.6,7.65,(3xm,2H,NH),6.7-7.5(b,2HNH), 6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.52(d,1H,J=5,2Hz,H ₁₄), 5.5 (d,1H,OH,J=6Hz), 3.9,3.6(2x,m1H, CHNH), 3.4(t,1H,H ₁₁ ,J=6Hz), 3.3 (m,2H,H ₂₂), 1.4,1.45(2xs,3H,CH ₃ CS), 1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz)
R _{EX}	Example 22a 14-O-[(3-(R*)-(R)-Valylamino-1-(R*)-methyl-1-yl)sulfanyl]-acetyl]mutilin and 14-O-[(3-(S*)-(R)-Valylamino-1-(S*)-methyl-1-yl)sulfanyl]-acetyl]mutilin in the form of a hydrochloride (diastereoisomeric mixture) (d ₆ -DMSO): 8.3(m,1H,NHC=O),8.1(b,3H,NH ₃ ⁺), 6.15, 5.1 (2xm, H ₁₉ ,H ₂₀ ,H ₂₁), 5.52(d,1H,J=5,2Hz,H ₁₄), 3.9 (m,1H, a-H-valyl), 3.3-3.1 (4xm,4H, H ₁₁ , H ₂₂ , ,CHNH ₃ ⁺), 4.5 (b,1H,OH), 1.25 (b,3H,CH ₃ CS), 1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.9 (m,6H,CH(CH ₃) ₂), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz)
R _{EX}	Example 22b 14-O-[(3-(R*)-(R)-Valylamino-1-(S*)-methyl-1-yl)sulfanyl]-acetyl]mutilin and 14-O-[(3-(S*)-(R)-Valylamino-1-(R*)-methyl-1-yl)sulfanyl]-acetyl]mutilin in the form of a hydrochloride (diastereoisomeric mixture) (d ₆ -DMSO): 8.35(m,1H,NHC=O),8.1(b,3H,NH ₃ ⁺), 6.15, 5.1 (2xm, H ₁₉ ,H ₂₀ ,H ₂₁), 5.52(d,1H,J=5,2Hz,H ₁₄), 3.95 (m,1H, a-H-valyl), 3.75 (m,1H,CHNH), 3.2-3.5(3xm,3H, H ₁₁ , H ₂₂ ,), 4.5 (b,1H,OH), 1.25 (b,3H,CH ₃ CS), 1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.9 (m,6H,

R_{EX}	$CH(CH_3)_2$, 0.75,0.88 (2xd, $(CH_3)_{16}$, $(CH_3)_{17}$,J=5.4Hz)
	Example 23 14-O-[(3-(R/S)-Dimethylamino-methylenimino-cyclohexan-1-(R/S)-methyl-1-yl)-acetyl]mutilin in the form of a hydrochloride (d ₆ -DMSO): 9.2,8.1(2xb,2H,NH), 6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.52 (d,1H,J=5.2Hz,H ₁₄), 4.5 (d,1H,OH,J=6Hz), 3.7,(m1H, CHNH), 3.4 (t,1H,H ₁₁ ,J=6Hz), 3.3 (m,2H,H ₂₂),3.1(b,6H,N(CH ₃) ₂), 1.4,1.45 (2xs, 3H,CH ₃ CS), 1.18,1.45(2xs, $(CH_3)_{15}$, $(CH_3)_{18}$), 0.75,0.88 (2xd, $(CH_3)_{16}$, $(CH_3)_{17}$,J=5.4Hz)

In another aspect the present invention provides 14-O-(oximino-(C₃₋₈)cycloalkyl-sulfanyl methylcarbonyl)-pleuromutilins and 14-O-(hydrazone-(C₃₋₈)cycloalkyl-sulfanyl methylcarbonyl)-pleuromutilins, such as a compound of formula



5

wherein

R_{1B} has the meaning of R_{1A} as defined above,

R_{2B} has the meaning of R_{2A} as defined above,

R_{10B} has the meaning of R_{6A} as defined above,

10 the dotted line has the meaning as defined above,

m_B has the meaning of m_a as defined above,

R_{3B} is hydrogen or (C₁₋₆)alkyl,

X_B is -O-R_{4B} or -NR_{5B}R_{6B},

15 R_{4B} is hydrogen or (C₁₋₆)alkyl, optionally substituted by a group -NR_{7B}R_{8B},

R_{5B} and R_{6B} independently of each other are (C₁₋₄)alkyl,

R_{7B} and R_{8B} independently of each other are (C₁₋₄)alkyl, or


R_{7B} and R_{8B} together with the nitrogen atom to which they are attached form aliphatic heterocyclil, having 5 to 8 ring members, and

R_{9B} is hydrogen or (C₁₋₄)alkyl.

20

In a compound of formula I_B preferably

- R_{1B} has is hydrogen,
 - R_{2B} has is hydrogen,
 - the dotted line is not present (single bond),
 - m_B is 2, 3 or 4,
- 5 - R_{3B} is hydrogen or (C_{1-4})alkyl, such as methyl,
- X_B is as defined above,
 - R_{4B} is hydrogen or (C_{1-4})alkyl, such as ethyl, substituted by a group $-NR_{7B}R_{8B}$,
 - R_{5B} and R_{6B} are as defined above,
 - R_{7B} and R_{8B} independently of each other are (C_{1-4})alkyl, e.g. ethyl, or R_{7B} and R_{8B} together
- 10 with the nitrogen atom to which they are attached form pyrrolidine or piperidine,
- R_{9B} is as defined above, and
 - R_{10B} is hydrogen;
- e.g. including 14-O-(oximino-(C_{3-8})cycloalkyl-sulfanyl-methylcarbonyl)-pleuromutilins and 14-O-(hydrazone-(C_{3-8})cycloalkyl-sulfanyl-methylcarbonyl)-pleuromutilins, which are selected
- 15 from the group consisting of of compounds of formula





wherein R_{EX} is as set out in TABLE 3. 1H -NMR-data of the compounds described and obtained according, e.g. analogously, to a process as described in the examples, are also indicated in TABLE 3:

20

TABLE 3

R_{EX} 	Example 24 14-O-[(3-Hydroxyimino-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin (syn and anti forms) Syn*-form: (DMSO-d ₆): 10.33 (s, 1H, =NOH), 6.15, 5.07, 5.03 (3xm, H ₁₉ , H ₂₀ , H ₂₁), 5.55 (d, 1H, H ₁₄ , J=8.3Hz), 4.5 (d, 1H, 11-OH, J=6.1Hz), 3.25-3.45 (m, SCH, H ₁₁ , H ₂₂), 2.67 (m, 1H, H-2a'), 1.35, 1.05 (2xs, (CH ₃) ₁₅ , (CH ₃) ₁₈), 0.8, 0.62 (2xd, (CH ₃) ₁₆ , (CH ₃) ₁₇ , J=7Hz). Anti*-form: (DMSO-d ₆): 10.36 (s, 1H, =NOH), 6.15, 5.07, 5.02 (3xm, H ₁₉ , H ₂₀ , H ₂₁), 5.55 (d, 1H, H ₁₄ , J=8.3Hz), 4.5 (d, 1H, 11-OH, J=6.1Hz), 3.25-3.45 (m, SCH, H ₁₁ , H ₂₂), 2.74 (m, 1H, H-2a') 1.35, 1.05 (2xs, (CH ₃) ₁₅ , (CH ₃) ₁₈), 0.8, 0.62 (2xd, (CH ₃) ₁₆ , (CH ₃) ₁₇ , J=7Hz).
--------------	--


R_{EX} 	<p>(CH₃)₁₇, J=6.8Hz)</p> <p>Example 26 14-O-[(3-(2-Diethylamino-ethoxyimino)-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl]mutilin in the form of a hydrochloride (syn/anti mixture) (DMSO-d₆): 9.9 (bs, 1H, NH⁺), 6.15, 5.07, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.1Hz), 4.3 (m, 2H, OCH₂), 3.1-3.4 (m, NCH₂, H₁₁, H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)</p>
R_{EX} 	<p>Example 27a 14-O-[(E*-Hydroximino-cyclohexan-3-(R*)-yl)-sulfanyl]-acetyl]mutilin (d₆-DMSO): 10.31(s, 1H, HON=C), 6.15, 5.1 (2xm, H₁₉, H₂₀, H₂₁), 5.52 (d, 1H, J=5.2Hz, H₁₄), 4.55 (d, 1H, OH, J=5Hz) 3.4(t, 1H, H₁₁, J=5Hz), 3.3 (m, 2H, H₂₂), 2.95 (m, 1H, SCH), 2.78, 1.95 (2xm, 2H, CH₂C=N), 2.57, 2.09(2xm, 2H, CH₂=C=N), 1.18, 1.45 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.75, 0.88 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=5.4Hz). [α]_D=15.87°(c=1, MeOH)</p> <p>Example 27b 14-O-[(E*-Hydroximino-cyclohexan-3-(S*)-yl)-sulfanyl]-acetyl]mutilin (d₆-DMSO): 10.31(s, 1H, HON=C), 6.15, 5.1 (2xm, H₁₉, H₂₀, H₂₁), 5.52 (d, 1H, J=5.2Hz, H₁₄), 4.50 (d, 1H, OH, J=5Hz) 3.4(t, 1H, H₁₁, J=5Hz), 3.3 (m, 2H, H₂₂), 2.95 (m, 1H, SCH), 2.78, 1.95(2xm, 2H, CH₂C=N), 2.57, 2.09(2xm, 2H, CH₂=C=N), 1.18, 1.45 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.75, 0.88 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=5.4Hz). [α]_D=38.5°(c=1, MeOH)</p>
R_{EX} 	<p>Example 27c 14-O-[(Z*-Hydroximino-cyclohexan-3-(R*)-yl)-sulfanyl]-acetyl]mutilin (d₆-DMSO): 10.31(s, 1H, HON=C), 6.15, 5.1 (2xm, H₁₉, H₂₀, H₂₁), 5.52 (d, 1H, J=5.2Hz, H₁₄), 4.50 (d, 1H, OH, J=5Hz) 3.45 (t, 1H, H₁₁, J=5Hz), 3.3 (m, 2H, H₂₂), 2.90(m, 1H, SCH), 3.05, 2.05 (2xm, 2H, CH₂C=N), 2.2(m, 2H, CH₂=C=N), 1.18, 1.45(2xs, (CH₃)₁₅, (CH₃)₁₈), 0.75, 0.88 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=5.4Hz). [α]_D=13.62°(c=1, MeOH)</p> <p>Example 27d</p>

14-O-[(Z*-Hydroximino-cyclohexan-3-(S*)-yl)-sulfanyl]acetyl]mutilin

(d₆-DMSO): 10.31(s,1H,HON=C), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5.2Hz,H₁₄), 4.50 (d,1H,OH,J=5Hz), 3.45(t,1H, H₁₁,J=5Hz), 3.3 (m,2H,H₂₂), 2.90(m,1H,SCH), 3.05,2.05 (2xm, 2H,CH₂C=N), 2.2(m,2H,CH₂=C=N), 1.18,1.45 (2xs,(CH₃)₁₅, (CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz). [α]_D=-42.83°(c=1, MeOH)

Example 28a

R_{EX}



14-O-[(E-Hydroximino-cyclohexan-3-(R/S)-methyl-1-yl)-sulfanyl]acetyl]mutilin


(d₆-DMSO): 10.31(s,1H,HON=C), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5.2Hz,H₁₄), 4.50 (d,1H,OH,J=5Hz), 3.45(t,1H,H₁₁, J=5Hz), 3.25(m,2H,H₂₂), 1.25 (s,3H,CH₃, CH₃CS) 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

Example 28b

14-O-[(Z-Hydroximino-cyclohexan-3-(R/S)-methyl-1-yl)-sulfanyl]acetyl]mutilin

(d₆-DMSO): 10.31(s,1H,HON=C), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5.2Hz,H₁₄), 4.50 (d,1H,OH,J=5Hz), 3.45 (t,1H, H₁₁, J=5Hz), 3.25(m,2H,H₂₂), 2.7 (d,1H,CHC=N, J=12Hz), 1.25 (s,3H, CH₃, CH₃CS) 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd, (CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

R_{EX}




Example 29

14-O-[(Z/E-Hydroximino-cyclohexan-3-(R/S)-methyl-5-(R/S)-methyl-1-yl)-sulfanyl]acetyl]mutilin

(d₆-DMSO): Diastereoisomers: 10.2,10.28(3xs,1H,HON=C), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5.2Hz,H₁₄), 4.50 (d,1H,OH, J=5Hz), 3.45(t,1H,H₁₁,J=5Hz), 3.25(m,2H,H₂₂), 3.25,1.7 (2xm, 2H,CH₂C=N), 1.3,1.34 (2xs,3H,CH₃, CH₃CS), 1.18,1.45 (2xs, (CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).

MS-ESI : 534 (M+1)

R_{EX}




Example 30

14-O-{{[3-(2-Diethylamino-ethoxyimino)-cyclohexan-(R/S)-yl]-sulfanyl]acetyl}-mutilin hydrochloride (E/Z mixture)}

(DMSO-d₆): 9.7 (bs,1H,NH⁺), 6.15,5.07,5.03 (3xm,H₁₉,H₂₀,H₂₁), 5.55 (d,1H, ,H₁₄,J=8.0Hz), 4.5,4.25 (2xm,2H,OCH₂), 3.0-3.45 (m, NCH₂, H₁₁, H₂₂), 1.35,1.05 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.8,0.62 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=6.8Hz)

R_{EX}



Example 31


14-O-{{[[(E/Z)-Dimethylaminimino-cyclohexan-3-(R/S)-1-yl]-sulfanyl]acetyl}-mutilin

(d₆-DMSO): Diastereoisomers: 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5.2Hz,H₁₄), 4.50 (d,1H,OH,J=5Hz), 3.45(t,1H,H₁₁,J=5Hz), 3.3(m,2H,H₂₂), 3.2, 2.8 (2xm,1H,CHS), 2.95,1.85 (2xm,2H, CH₂C=N), 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd, (CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

R_{EX}

Example 32a

14-O-[(E*-Hydroximino-cycloheptan-3-(R/S)-yl)-sulfanyl]-



acetyl]mutilin


NMR(d_6 -DMSO): 10.35(s,1H, HON=C), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52 (d,1H,J=5.2Hz,H₁₄), 4.5(d,1H,OH,J=6.1Hz), 3.4(t,1H,H₁₁,J=6.1Hz), 3.3 (m,2H,H₂₂), 1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇, J=5.4Hz).

Example 32b

14-O-[(Z*-Hydroximino-cycloheptan-3-(R/S)-yl)-sulfanyl]acetyl]mutilin

(d_6 -DMSO): 10.35(s,1H,HON=C), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5.2Hz,H₁₄), 4.5 (d,1H,OH,J=5Hz)3.4(t,1H,H₁₁,J=5Hz), 3.3 (m,2H,H₂₂), 3.05 (m,1H,SCH); 1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇, J=5.4Hz)

R_{EX}




Example 33

14-O-[(3-(2-Diethylamino-ethoxyimino)-cyclohept-(R/S)-yl)-sulfanyl]acetyl]mutilin hydrochloride (E/Z mixture)

(DMSO-d₆): 9.85 (bs,1H,NH⁺), 6.15,5.06,5.03 (3xm,H₁₉,H₂₀,H₂₁), 5.55 (d,1H,H₁₄,J=8.5Hz), 4.52,4.53 (2xd,1H,11-OH,J=6.2Hz), 4.28 (m,2H,OCH₂), 3.0-3.45 (m, NCH₂, H₁₁, H₂₂), 1.35,1.05 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.8,0.62 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=6.8Hz)

R_{EX}




Example 34

14-O-[(3-(2-Pyrrolinine-1-yl-ethoxyimino)-cyclohept-1-(R/S)-yl)-sulfanyl]acetyl]mutilin hydrochloride (E/Z mixture)

(DMSO-d₆): 10.2 (bs,1H,NH⁺), 6.15,5.08,5.05 (3xm,H₁₉,H₂₀,H₂₁), 5.58 (d,1H,H₁₄,J=8.3Hz), 4.53,4.57 (2xd,1H,11-OH,J=6.1Hz), 4.26 (m,2H,OCH₂), 3.0-3.45 (m, NCH₂, H₁₁, H₂₂), 1.38,1.08 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.83,0.64 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=6.8Hz).

R_{EX}




Example 35

14-O-[(3-(2-Piperidine-1-yl-ethoxyimino)-cyclohept-(R/S)-yl)-sulfanyl]acetyl]mutilin in the form of a hydrochloride (E/Z mixture)

¹HNMR(DMSO-d₆): 10.0 (bs,1H,NH⁺), 6.15,5.06,5.03 (3xm,H₁₉,H₂₀,H₂₁), 5.55 (d,1H,H₁₄,J=8.4Hz), 4.5,4.55 (2xd,1H,11-OH,J=6.2Hz), 4.32 (m,2H,OCH₂), 2.8-3.5 (m, NCH₂, H₁₁, H₂₂), 1.35,1.05 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.8,0.62 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=6.8Hz)

In another aspect the present invention provides a compound of formula




wherein

- R_{1C} has the meaning of R_{1A} as defined above,
R_{2C} has the meaning of R_{2A} as defined above,
the dotted line has the meaning as defined above,
R_{4C} has the meaning of R_{6A} as defined above, and
5 R_{3C} is amino, (C₁₋₄)alkylamino, di(C₁₋₄)alkylamino, the residue of an amino acid, hydroxy, or (C₁₋₄)alkoxy.

In a compound of formula I_C preferably

- R_{1C} is hydrogen,
 - 10 - R_{2C} is hydrogen,
 - R_{4C} is hydrogen,
 - the dotted line is not present (single bond), and
 - R_{3C} is amino, di(C₁₋₄)alkylamino, or the residue of an amino acid;
- e.g. including pleuromutilins which are selected from the group consisting of compounds
15 of formula



wherein R_{EX} is as set out in TABLE 4. ¹H-NMR-data of the compounds described and obtained according, e.g. analogously, to a process as described in the examples are also indicated in TABLE 4:

20

TABLE 4

R_{EX}	<p>Example 36a 14-O-[(3S,3aS,6S,6aR)-6-Amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin in the form of a hydrochloride - (DMSO-d₆): 8.3 (bs, 3H, NH₃⁺), 6.15, 5.05, 5.02(3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, 8.2Hz, H₁₄), 4.65, 4.55(2xm, H₁₁-OH, H-3a', H6a'), 3.6-4.1 (m, 5H, H-2', H-5', H-6'), 3.3-3.5 (m, 4H, H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.5Hz)</p>
	<p>Example 36b 14-O-[(3R,3aS,6S,6aR)-6-Amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin-hydrochloride</p>


(DMSO-d₆): 8.3 (bs, 3H, NH₃⁺), 6.15, 5.07, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.2Hz), 4.60, 4.7 (2xm, H-3a', H6a'), 3.6-4.1 (m, 5H, H-2', H-5', H-6'), 3.3-3.5 (m, 4H, H₁₁, H-3', H₂₂), 1.35, 1.05, (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.9Hz)

Example 36c

14-O-{{(3S,3aS,6R,6aR)-6-Amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl}-acetyl}-mutilin-hydrochloride

(DMSO-d₆): 8.25 (bs, 3H, NH₃⁺), 6.15, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.4Hz), 4.60 (m, 2H, H-3a', H6a'), 3.55-4.2 (m, 5H, H-2', H-5', H-6'), 3.35-3.5 (m, 4H, H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.9Hz)

Example 37



14-O-{{(3S,3aS,6S,6aR)-6-Dimethylamino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl}-acetyl}-mutilin in the form of a hydrochloride

(DMSO-d₆): 11.25 (bs, 1H, NH⁺), 6.15, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.2Hz), 4.60 (m, 1H, H3a'), 3.3-4.1 (m, H-2', H-5', H-6', H-6a', H₁₁, H-3', H₂₂), 2.8, 2.7 (2xd, 6H, NH⁺(CH₃)₂, J=4.5Hz), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.9Hz)

Example 38a

14-O-{{(3S,3aS,6S,6aR)-6-((R)-Amino-3-methyl-butyryl-amino)-hexahydro-furo[3,2-b]furan-3-ylsulfanyl}-acetyl}-mutilin in the form of a hydrochloride

(DMSO-d₆): 8.65 (d, 1H, NH, J=8.2Hz), 7.8 (bs, 3H, NH₃⁺), 6.15, 5.07, 5.02 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, 5.2Hz, H₁₄), 4.55, 4.45 (2xm, 3H, H₁₁-OH, H-3a', H6a'), 3.6-4.2 (m, 5H, H-2', H-5', H-6'), 3.4-3.5 (m, 4H, H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.88, 0.92 (2xd, (CH₃)₂CH, J=6.8Hz); 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)

Example 38b

14-O-{{(3R,3aS,6S,6aR)-6-((R)-Amino-3-methyl-butyryl-amino)-hexahydro-furo[3,2-b]furan-3-ylsulfanyl}-acetyl}-mutilin in the form of a hydrochloride


(DMSO-d₆): 8.8 (d, 1H, NH, J=7.1Hz), 8.15 (bs, 3H, NH₃⁺), 6.15, 5.07, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, 7.9Hz, H₁₄), 4.6, 4.4 (2xm, 2H, H-3a', H6a'), 3.6-4.2 (m, 5H, H-2', H-5', H-6'), 3.2-3.5 (m, 4H, H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.89, 0.91 (d, (CH₃)₂CH, J=6.8Hz), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)

Example 38c

14-O-{{(3S,3aS,6R,6aR)-6-((R)-Amino-3-methyl-butyryl-amino)-hexahydro-furo[3,2-b]furan-3-ylsulfanyl}-acetyl}-mutilin in the form of a hydrochloride

(DMSO-d₆): 8.4 (d, 1H, NH, J=7.8Hz), 8.1 (bs, 3H, NH₃⁺), 6.15, 5.06, 5.02 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, 8.2Hz, H₁₄), 4.6, 4.5 (2xm, 2H, H-3a', H6a'), 3.6-4.4 (m, 5H, H-2', H-5', H-6'), 3.3-3.5 (m, 4H, H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.94, 0.90 (d, (CH₃)₂CH, J=6.8Hz), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)

R_{EX}



Example 39a

14-O-{[(3S,3aS,6R,6aR)-6-Hydroxy-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin

(DMSO-d₆): 6.15, 5.07, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.3Hz), 4.85 (d, 1H, H-6'-OH, J=6.4Hz), 4.5 (d, 1H, 11-OH, J=6.1Hz), 3.65-4.45 (m, H-3a', H-6a', H-2', H-5', H-6'), 3.3-3.45 (m, H-5', H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.9Hz)

Example 39b

14-O-{[(3R,3aS,6R,6aR)-6-Hydroxy-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin

(DMSO-d₆): 6.15, 5.06, 5.03 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.3Hz), 4.8 (d, 1H, H-6'-OH, J=5.7Hz), 4.5 (d, 1H, 11-OH, J=6.1Hz), 3.7-4.45 (m, H-3a', H-6a', H-2', H-5', H-6'), 3.2-3.5 (m, H-5', H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)


Example 39c

14-O-{[(3S,3aS,6S,6aR)-6-Hydroxy-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin

(DMSO-d₆): 6.1, 5.07, 5.02 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.3Hz), 5.2 (d, 1H, H-6'-OH), 3.55-4.55 (m, 11-OH, H-3a', H-6a', H-2', H-5', H-6'), 3.3-3.45 (m, H₁₁, H-3', H₂₂), 1.35, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz)

In another aspect the present invention provides 14-O-(hydroxy- or oxo)-(heterocycl-sulfanyl-methylcarbonyl)-pleuromutilins, wherein heterocycl is an aliphatic ring of 4 to 8 ring members, preferably 5 to 7, comprising one nitrogen as the heteroarom, e.g. a compound of formula

5 formula



wherein

R_{1D} has the meaning of R_{1A} as defined above,

R_{2D} has the meaning of R_{2A} as defined above,


10 R_{4D} has the meaning of R_{6A} as defined above,

the dotted line has the meaning as defined above, and

R_{3D} is aliphatic heterocycl of 4 to 8 ring members, and comprising one nitrogen atom as the heteroatom, or (C₄₋₈)cycloalkyl, which heterocycl or cycloalkyl is substituted by hydroxy or oxo.

In a compound of formula I_D preferably

- R_{1D} is hydrogen or deuterium,
 - R_{2D} is hydrogen or deuterium,
- 5 - the dotted line is not present (single bond),
- R_{3D} is as defined above, e.g. heterocyclyl has preferably 5 to 7 ring members, e.g. heterocyclyl is attached to the sulphur in a compound of formula ID via a carbon bond; such as hydroxypyrrrolidino, hydroxypiperidino, oxo-perhydroazepinyl; and cycloalkyl is preferably (C_{5-6})cycloalkyl, e.g. cyclopentanonyl,
- 10 - R_{4D} is hydrogen or deuterium,
e.g. including 14-O-(hydroxy- or oxo-heterocyclyl-sulfanyl-methylcarbonyl)-pleuromutilins, wherein heterocyclyl is an aliphatic ring of 4 to 8 ring members, preferably 5 to 7, comprising one nitrogen as the heteroarom, which are selected from the group consisting of e.g. including pleuromutilins which are selected from the group consisting of compounds of
- 15 formulae



wherein R_{EX} is as set out in TABLE 5. The compounds of TABLE 5 are compounds of formula I_{EX} , with the exception of the compound of Example 41 which is a compound of formula I''_{EX} . 1H -NMR-data of the compounds described and obtained according, e.g.

- 20 analogously, to a process as described in the examples are also indicated in TABLE 5:

TABLE 5

 R_{EX} HO 	Example 40 14-O-[(3-R*-Hydroxypyrrolidine-4-(R*)yl) -sulfanyl-acetyl]-mutilin and 14-O-[(3-S*-Hydroxypyrrolidine-4-(S*)yl) -sulfanyl-acetyl]-mutilin in the form of a hydrochloride (diastereoisomeric mixture) (d-6-DMSO): 9.4,9.65 (2xb,2H,NH ₂ ⁺), 3.6,3.2(2xm ,4H,CH ₂ NCH ₂), 4.45(m,1H,CHO), 3.45-3.32(m,3H,H ₁₁ H ₂₂), 3.95 (m,1H,CHS), 1.18,1.45 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz 0.98)
------------------------	--

	Example 41 2,2,4-Trideutero-14-O-[(3-(S*)-hydroxy-piperidine-4-(S*)-yl)-sulfanyl]-acetyl]mutilin in the form of a deuterchloride (d ₆ -DMSO,350K): 8.05 (b,3H,NH ₃ ⁺), 4.25-4.1(m,3H,CH ₂ N, NHCHC=O), 3.75(m,1H,CHO), 3.45-3.32(m,3H,H ₁₁ H ₂₂), 2.89 (m,1H,CHS), 1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.9 (m,6H,CH(CH ₃) ₂), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz 0.98). The signals of the 2,2'- and 4-protons of the tricyclic moiety are missing in that spectrum. Mass Spectroscopy (MS): m/e: 496
	Example 42 14-O-[(3R*-Hydroxypiperidin-4-(R*)-yl)-sulfanyl-acetyl]mutilin in the form of a hydrochloride + 14-O-[(3S*-Hydroxypiperidin-4-(S*)-yl)-sulfanyl-acetyl]mutilin in the form of a hydrochloride (d ₆ -DMSO,350K): 8.05 (b,3H,NH ₃ ⁺), 4.25-4.1(m,3H,CH ₂ N, NHCHC=O), 3.75(m,1H,CHO), 3.45-3.32(m,3H,H ₁₁ H ₂₂), 2.89 (m,1H,CHS), 1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.9 (m,6H,CH(CH ₃) ₂), 0.75,0.88(2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz 0.98)
	Example 43 14-O-[((Azepan-2-one-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin (d ₆ -DMSO): 6.15, 5.1 (2xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.52(d,1H,J=5,2Hz,H ₁₄), 3.4(m,1H,H ₁₁), 3.3 (m,2H,H ₂₂), 3.1 (m,2H,SCH,CHN), 1.18,1.45(2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.75,0.88 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=5.4Hz)
	Example 44 14-O-{[(3-Oxo-cyclopantan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin (CDCl ₃): 6.45,5.35,5.2(3xm,H ₁₉ ,H ₂₀ ,H ₂₁), 5.8 (d,1H, ,H ₁₄ ,J=8.4Hz), 3.6 (m, 1H, SCH), 3.35 (m,1H,11-OH), AB-system(v _A = 3.25, v _B = 3.17, 2H, H ₂₂ , J=14.8Hz), 2.65 (m,1/2H,H-2a'), 2.6 (m,1/2H,H-2a'), 1.45,1.18 (2xs,(CH ₃) ₁₅ ,(CH ₃) ₁₈), 0.9,0.75 (2xd,(CH ₃) ₁₆ ,(CH ₃) ₁₇ ,J=6.8Hz)

- Novel compounds provided by the present invention, including compounds, the formulae of which are as set out in TABLE 1 to TABLE 5, and compounds of formulae I_A, I_B, I_C, I_D, I_{EX}, I'_{EX} and I''_{EX} are herein designated as "novel compound(s) of (according to) the present invention". "The residue of an amino acid", whenever defined in any one of the novel compounds of the present invention includes that part of an amino acid, e.g. including natural and synthetic amino acids, , e.g. valine and other amino acids as defined herein, most preferably valine; which remains if the hydroxy group from the carboxylic acid group is split off, e.g. in case of valine [HO-CO-CH(NH₂)-CH(CH₃)₂] the residue -CO-CH(NH₂)-CH(CH₃)₂.
- 5 In a novel compound of the present invention each single defined substituent may be a preferred substituent, e.g. independently of each other substituent defined.
- 10 In a novel compound of the present invention each single defined substituent may be a preferred substituent, e.g. independently of each other substituent defined.

In a novel compound of the present invention each single defined substituent may be a preferred substituent, e.g. independently of each other substituent defined.

A novel compound of the present invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and a solvate.

5 In another aspect the present invention provides a novel compound of the present invention in the form of a salt.

A salt of a novel compound of the present invention includes a pharmaceutically acceptable salt, e.g. including a metal salt or an acid addition salt. Metal salts include for example alkali or earth alkali salts; acid addition salts include salts of a compound of formula I with an acid, 10 e.g. hydrogen fumaric acid, fumaric acid, naphthalin-1,5-sulphonic acid, phosphoric acid, tartaric acid, citric acid, hydrochloric acid, deuteriochloric acid; preferably hydrochloric acid. A novel compound of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa. A novel compound of the present invention in free form or in the form of a salt and in the form of a solvate may be converted into a 15 corresponding compound in free form or in the form of a salt in unsolvated form; and vice versa.


A novel compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis-, trans-conformers. A compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form 20 of diastereoisomeres and mixtures thereof, e.g. racemates. For example a novel compound of the present invention may comprise the residue of an amino acid. In such amino acid residue the carbon atom to which the amino group is attached may be an asymmetric carbon atom and the amino group attached may thus be in the R- or S-configuration. A novel compound of the present invention may comprise a cycloalkyl, e.g. attached to the sulfanyl 25 group, which cycloalkyl may be further substituted, and said substitutents may exist in the cis or in the trans conformation. E.g., the carbon atom of a cycloalkyl group to which the sulfanylgroup is attached may be asymmetric, e.g. if said cycloalkyl is further substituted, and substitutents attached to said cycloalkyl group may be in the R- or in the S- configuration. E.g., a novel compound of the present invention also may comprise an oxime 30 group. The hydroxgroup attached to the imino group may be in syn- or in anti-configuration. Isomeric mixtures may be separated as appropriate, e.g. according, e.g. analogously, to a method as conventional, to obtain pure isomers. The present invention includes a novel compound of the present invention in any isomeric form and in any isomeric mixture.

The present invention also includes tautomers of a novel compound of the present invention

where such tautomers can exist.

Any compound described herein, e.g. a novel compound of the present invention, may be prepared as appropriate, e.g. according to a method as conventional, e.g. analogously, e.g. 5 or as specified herein.

In another aspect the present invention provides a process for the production of a compound of formula



10 wherein

R_{1P} has the meaning of R_{1A} as defined above,


R_{2P} has the meaning of R_{2A} as defined above,

R_{3P} has the meaning of R_{6A} as defined above,

the dotted line has the meaning as defined above, and


15 R_P has the meaning as set out in any one of patent claims 6 to 11,
comprising the steps

a. reacting a compound of formula



wherein R_{1P} and R_{2P} are as defined above, and the dotted line has the meaning as
20 defined above,

with thiourea and subsequent reduction to obtain a compound of formula



wherein R_{1P} and R_{2P} are as defined above,

- b. reacting a compound of formula II_P obtained in step a, with a compound of formula

5 R_P-H

wherein R_P is as defined above, in a reactive form, e.g. a mesylate or a tosylate, optionally in a protected form,

to obtain a compound of formula I_P (i.e. novel compound of the present invention), or to obtain a pre-form of a compound of formula I_P ,

- 10 c. optionally further reacting a pre-form obtained in step b. to obtain a compound of formula I_P , e.g. introducing deuterium to obtain a compound of formula I_P wherein the substituents are as defined above,
and
d. isolating a compound of formula I_P obtained in step b. or in step c. from the reaction
15 mixture.

R_P is

- substituted (C_{4-8})cycloalkyl,
 - substituted phenyl,

20 - substituted aliphatic heterocyclyl, having 4 to 8 ring members and comprising as a heteroatom 1 or 2 nitrogen atoms,

 - alkyl, substituted by (substituted) amino,
 - alkyl substituted by heterocyclyl, or
 - substituted, bicyclic aliphatic heterocyclyl, comprising in each ring 5 ring members and one oxygen heteroatom,
- e.g. including the meanings of R_P in the novel pleuromutilins of the present invention, e.g. such as set out in patent claims 6 to 11.

- A process provided by the present invention may e.g. be carried out analogously to processes as set out in any of the patent references cited herein, e.g. analogously to a process for the production of compounds as described in patent literature cited herein, such 5 as in WO0109095, WO0204414 and WO0222580, or as described herein.
- All patent references cited herein are introduced by reference, especially with respect to the claim scopes and meanings of the substituents, e.g. including the preferred meanings of the substituents, and with respect to production processes.
- A pleuromutilin of the present invention includes the novel compounds of the present 10 invention of formula I_P. A pleuromutilin of the present invention includes one or more, preferably one, pleuromutilins of the present invention, e.g. one pleuromutilin or a combination of different pleuromutilins of the present invention.
- We have found that novel compounds of the present invention, including compounds of 15 formula I_P, exhibit pharmacological activity similar to pleuromutilins in similar indications as described in WO0109095, WO0204414 and WO0222580, e.g. in test systems similar as described in WO0109095, WO0204414 and WO0222580, and additionally in test systems described herein. Compounds of formula I_P are therefore useful as pharmaceuticals.
- 20 In another aspect the present invention provides a compound of formula I_P for use as a pharmaceutical, preferably as an antimicrobial, such as an antibiotic, e.g. and as an anti-anaerobic, including the use as a pharmaceutical in the treatment of diseases mediated by Mycobacterium, such as Mycobacterium tuberculosis
- 25 In another aspect the present invention provides a compound of formula I_P for use in the preparation of a medicament for the treatment of microbial diseases, for example of diseases mediated by bacteria, e.g. selected from Staphylococci, Streptococci, Enterococci, Mycobacterium, e.g. Mycobacterium tuberculosis; e.g. and of diseases mediated by Mycoplasms, Chlamydia and obligatory anaerobes.
- 30 In another aspect the present invention provides a method of treatment of microbial diseases, for example of diseases mediated by bacteria, e.g. selected from Staphylococci, Streptococci, Enterococci, Mycobacterium, e.g. Mycobacterium tuberculosis; e.g. and of diseases mediated by Mycoplasms, Chlamydia and obligatory anaerobes, which method

comprises administering to a subject in need of such treatment an effective amount of a novel compound of the present invention, e.g. including a compound of formula I_P; e.g. in the form of a pharmaceutical composition.

5 Treatment includes treatment and prophylaxis.

For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmacokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.05 g to about 5.0 g, of a novel compound of the present invention; conveniently administered, for example, in divided doses up to four times a day.

For treatment of diseases mediated by *Mycobacterium* with a pleuromutilin of the present invention similar considerations apply.

15

A novel compound of the present invention may be administered by any conventional route, for example enterally, e.g. including nasal, buccal, rectal, oral administration; parenterally, e.g. including intravenous, intramuscular, subcutaneous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration;

20 e.g. in form of coated or uncoated tablets, capsules, injectable solutions or suspensions, e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories.

For administration of a pleuromutilin of the present invention in diseases mediated by *Mycobacterium*, similar considerations apply, with the exception of topical administration.

25

The novel compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt, e.g. an acid addition salt or metal salt; or in free form; optionally in the form of a solvate. The novel compounds of the present invention in the form of a salt exhibit the same order of activity as the novel compounds of the present invention in free form; optionally in the form of a solvate.

30 For administration of a pleuromutilin of the present invention in diseases mediated by *Mycobacterium* similar considerations apply.

A novel compound of the present invention may be used for pharmaceutical treatment

according to the present invention alone, or in combination with one or more other pharmaceutically active agents. Such other pharmaceutically active agents e.g. include other antimicrobials, e.g. including antibiotics, e.g. cephalosporins, penicillins, erythromycins, tetracyclines.

- 5 Similar considerations apply for a pleuromutilin of to the present invention in diseases mediated by Mycobacterium, but appropriate other pharmaceutically active agents includes agents known to be active in the treatment of diseases mediated by Mycobacterium, such as Rifampicin (Rifampicin®), Streptomycin (Streptomycin®), Ethambutol (Ethambutol®), Pyrizinamid (Pyrizinamid®).
- 10 Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instruction for co-administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instruction for simultaneous or sequential administration are given.

- 15 In another aspect the present invention provides a pharmaceutical composition comprising a novel compound of the present invention, e.g. a compound of formula I_P, in association with at least one pharmaceutical excipient, e.g. appropriate carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners,
- 20 fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers; e.g. further comprising another pharmaceutically active agent.
Pharmaceutical composition comprising pleuromutilins of the present invention for administration in diseases mediated by Mycobacterium may comprise similar excipient as
- 25 described above.


- 30 In another aspect the present invention provides a pharmaceutical composition comprising a pleuromutilin of the present invention in association with at least one pharmaceutical excipient, and further comprising another pharmaceutically active agent useful in the treatment of Mycobacterium, e.g. M.tuberculosis, infections, such as Rifampicin (Rifampicin®), Streptomycin (Streptomycin®), Ethambutol (Ethambutol®), Pyrizinamid (Pyrizinamid®).

Such compositions may be manufactured according, e.g. analogously to a method as conventional, e.g. by mixing, granulating, coating, dissolving or lyophilizing processes. Unit dosage forms may contain, for example, from about 0.5 mg to about 1500 mg, such as 1 mg to about 500 mg.


5

Pleuromutilins of the present invention for administration in diseases mediated by *Mycobacterium tuberculosis* may be administered in a similar mode and in similar dosages as Rifampicin or Streptomycin.

- 10 A pleuromutilin of the present invention is preferably selected from the group consisting of a compound of formula I-US4278674, a compound of formula I-EP0153277, a compound of formula I-WO0109095, a compound of formula I-WO0204414, a compound of formula I-WO0222580, a compound of TABLE 1, a compound of formula I_B, or a of formula I_D; e.g. including
- 15 - a compound of formula I-Tiamulin,
- a compound of formula I-Valnemulin, e.g. in the form of a hydrochloride;
- a compound of formula




- e.g. in the form of a hydrochloride;
- 20 - a compound of formula




I-PREF2

e.g. in the form of a hydrochloride,
- a compound of formula




I-PREF3

5 e.g. in the form of a hydrochloride,
- a compound of formula




I-PREF4

e.g. in the form of a hydrochloride,
- a compound of formula




I-PREF5

e.g. in the form of a hydrochloride,
- a compound of formula



I-PREF6


5 e.g. in the form of a hydrochloride,
- a compound of formula



I-PREF7

and

- a compound of



e.g. in the form of a hydrochloride.

- Activity against strains of *Mycobacterium*, e.g. *M.tuberculosis* may be determined according
5 to the following General Test Procedure:

General Test procedure

Is carried out according to the known and appropriate Agar Dilution Test.

- Agar is used as a substrate. Shortly before solidification of the Agar TEST COMPOUNDS in
10 different concentrations are added and mixed into the still liquid agar mass (according to the
Agar dilution test). Controls without TEST COMPOUNDS are also prepared for
determination of strain growth ability. The thus prepared agars are inoculated after
solidification with *Mycobacterium tuberculosis* strains. Incubation is carried out in normal
incubators at 37°C. As a nutrition medium Middlebrook 7H10 + OADC (Oleic, Albumin,
15 Dextrose, Catalase) Enrichment (pH 6.71- 6.73) is used.

The minimum inhibition concentration (MIC) which is the compound concentration in the agar
which inhibits 99% of strain growth, is determined after 3 weeks, 4 weeks and 5 weeks after
inoculation.

- 20 Pleuromutilins of the present invention show activity against strains of *Mycobacterium*, e.g.
M.tuberculosis and are thus useful in the treatment of infections caused by *Mycobacterium*.
Pleuromutilins of the present invention surprisingly are even active against resistant and
multiresistant *M.tuberculosis* strains, e.g. strains which are resistant against treatment with
known pharmaceuticals useful in the treatment of tuberculosis, e.g. Isoniacid, Rifampicin,
25 Streptomycin.

In the following Examples all temperatures are in degree Centigrade and are uncorrected.

The following abbreviations are used:

BOC:	tert.butoxyxcarbonyl	DCC:	dicyclohexylcarbodiimide
DMF:	N,N-dimethylformamide	DMSO:	dimethylsulfoxide
EDC: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride			
EtAc:	ethyl acetate	EtOH:	ethanol
5 HOBT:	1-hydroxybenzotriazole	MeOH:	methanol
MS:	mass spectroscopy	RT:	room temperature
TBAF:	tetra-n-butylammonium fluoride	TFA:	trifluoroacetic acid
THF :	tetrahydrofuran		

Chromatography is carried out on silica gel.

Preparation Examples

I. Preparation of (novel) pleuromutilins of the present invention

Example I-A

- 5 14-O-[(N-(3-Methyl-2(R)-amino-butyryl)-piperidine-3-yl)-sulfanylacetyl]-mutilin in the form of a hydrochloride

I-AA) 14-O-[(N-BOC-Piperidin-3(S)-yl)-sulfanylacetyl]-mutilin

Method 1:

532 mg of 22-O-tosyl-pleuromutilin are added to a solution of 217 mg of N-BOC-piperidine-

- 10 3(S)-thiol and 112 mg potassium tert. butylate in 10 ml of THF, the mixture obtained is stirred forer 3 hours, the mixture obtained is distributed between EtAc and brine, the organic phase obtained is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography. 14-O-[(N-BOC-Piperidin-3(S)-yl)-sulfanylacetyl]-mutilin is obtained.

Method 2:

- 15 A solution of 1.97 g of 22-mercaptop-pleuromutilin, 1.39 g of N-BOC-3(R)-methylsulfonyloxy-piperidine and 0.12 g of sodium in 50 ml of EtOH is heated to 90° for 12 hours, from the mixture obtained solvent is evaporated and the evaporation residue is subjected to chromatography. 14-O-[(N-BOC-piperidin-3-yl)-sulfanylacetyl]-mutilin is obtained.

¹H-MR(CDCl₃):6.45,5.35,5.2(3xm,H₁₉,H₂₀,H₂₁),5.74(d,1H,5,2Hz,H₁₄),3.35(d,1H,H₁₁,J=5.2Hz),

- 20 AB-system: 3.12,3.18, J=14.7Hz,H₂₂), 3.2,2.95,2.65,2.6(4xm,CH₂NCH₂), 2.85 (m,1H, SCH),1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88(2xd,(CH₃)₁₆, (CH₃)₁₇,J=5.4Hz)

I-AB) 14-O-[(N-(3-Methyl-2(R)-amino-butyryl)-piperidine-3-yl)-sulfanylacetyl]-mutilin in the form of a hydrochloride

A solution of 280 mg of 14-O-[(N-BOC-piperidin-3-yl)-sulfanylacetyl]-mutilin in 20 ml of

- 25 CH₂Cl₂ and 1 ml of TFA is stirred at RT for 30 minutes and from the mixture obtained solvent is evaporated. The evaporation residue obtained is treated with 40 ml of CH₂Cl₂, 55 mg of N-methyl-morpholine, 110 mg of N-BOC-(R)-valine and 105 mg of DCC are added and the mixture obtained is stirred for 3 hours. From the mixture obtained precipitated dicyclohexylurea is filtered off and the filtrate obtained is subjected to chromatography.

- 30 Purified 14-O-[(N-(3-Methyl-2(R)-amino-butyryl)-piperidine-3-yl)-sulfanylacetyl]-mutilin obtained is treated with TFA in CH₂Cl₂, solvent is evaporated and the evaporation residue obtained is treated with etheric HCl. 14-O-[(N-(3-Methyl-2(R)-amino-butyryl)-piperidine-3-yl)-sulfanylacetyl]-mutilin in the form of a hydrochloride is obtained.

¹H-NMR(d-6-DMSO,330K): 6.45,5.35,5.2(3xm,H₁₉,H₂₀,H₂₁), 5.74 (d,1H,5.2Hz,H₁₄), 5.45 (d,1H,NH,J=7.8Hz), 4.1 (m,1H,NHCHCO), 3.35 (d,1H,H₁₁,J=5.2Hz), AB-system: 3.12,3.18, J=14.7Hz,H₂₂), 3.2, 2.95, 2.65 ,2.6 (4xm,CH₂NCH₂), 2.8 (m,1H,SCH), 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz), 0.78,0.84 (2xd, (CH₃)₂CHJ=6.8Hz)

5

Example I-B

14-O-[(N-(3-Methyl-2(R)-amino-butyryl)-piperidine-3(S)-yl)-sulfanylacetyl]-2(S)-fluoro-mutilin in the form of a hydrochloride

10 **IBA) 14-O-(Tosyloxyacetyl)-2(S)-fluoro-mutilin**

To a solution of 500 mg of 14-O-(hydroxyacetyl)-2(S)-fluoro-mutilin (see e.g. Vyplel H., et al *J Fluorine Chem*; 23, 482 (1983)), in 5 ml of CH₂Cl₂ 450 mg of toluene sulfonic acid anhydride and 0.21 ml of pyridine are added and the mixture obtained is stirred for 4 hours at RT. The mixture obtained is diluted with CH₂Cl₂ and extracted with 1N HCl, aqueous 15 NaHCO₃ and H₂O. The organic phase obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography. 14-O-[tosyloxyacetyl]-2(S)-fluoro-mutilin is obtained.

IBB) 14-O-[(N-(3-Methyl-2(R)-amino-butyryl)-piperidine-3(S)-yl)-sulfanylacetyl]-2(S)-fluoro-mutilin in the form of a hydrochloride

20 is obtained starting from 14-O-[tosyloxyacetyl]-2(S)-fluoro-mutilin analogously to the method of Example IAB). Characterisation data see TABLE 1, Example 12.

Example I-C

14-O-[(3-Guanidino-phenylsulfanyl)-acetyl]mutilin in the form of a hydrochloride

25 **ICA) 14-O-[(3-Amino-phenylsulfanyl)-acetyl]-mutilin**

A solution of 0.92 g of sodium and 5g of 3-amino-thiophenol in 100 ml of dry EtOH is added to a solution of 21.3 g of 22-O-tosyl-pleuromutilin (see e.g. H.Egger et al., *J.Antibiotics* 29, 923 (1976)) in 250 ml of ethylmethylketone at 25° under careful temperature control. The mixture obtained is kept for 15 hours at 25°, filtered and the filtrate obtained is concentrated 30 under reduced pressure and subjected to chromatography. 14-O-[(3-Amino-phenylsulfanyl)-acetyl]-mutilin is obtained. ¹H-NMR(CDCl₃): 0.58(d, 3H, H₁₆, J=7.2Hz), 0.81 (d, 3H, H₁₇, J=7.3Hz), 1.02 (s, 3H, H₁₈), 1.32 (s, 3H, H₁₅), ABX-system(v_A= 1.2, v_B= 1.88, H_{13a},H_{13b}, J=16.1Hz, J=9.1Hz), 2.08(d,1H, H₄, J=2.1Hz), ABXY-system(v_A= 2.23, v_B= 2.19, H_{2a},H_{2b}, J=16.2Hz, J=9.1Hz, J=1.8Hz), 2.3(m,1H,H₁₀), 3.4 (d,1H,H₁₁, J=5.98Hz), AB-system (v_A=

3.81, $\nu_8 = 3.89$, 2H, H₂₂, J=14.1Hz), 5.18(dd,1H, H_{20a}, J=17.5Hz, J=1.6Hz), 5.29(dd,1H, H_{20b}, J=11Hz, J=1.6Hz), 5.51 (d,1H, H₁₄, J=8.3Hz), 6.05 (dd,1H,H₁₉, J=11Hz, J=17.5Hz), 7.0 (m,1H, arom.H), 7.18 (m2H, arom.H), 7.3t,1H, arom.H₅, J=8Hz).

ICB) 14-O-[(3-Guanidino-phenylsulfanyl)-acetyl]mutilin in the form of a hydrochloride

- 5 A solution of 2.4 g of 14-O-[(3-amino-phenylsulfanyl)-acetyl]mutilin, 1.5 g of cyanamide and 0.44 ml of HCl conc. in 20 ml of dioxane is stirred at room temperature for 28 hours. 14-O-[(3-Guanidino-phenylsulfanyl)-acetyl]mutilin in the form of a hydrochloride in crystalline form is obtained. Characterisation data see in TABLES above.

10 **Example I-D**

14-O-[(3R*-Hydroxypiperidin-4-(R*)yl) -sulfanyl-acetyl]mutilin and 14-O-[(3S*-Hydroxypiperidin-4-(S*)yl) -sulfanyl-acetyl]mutilin in the form of a hydrochloride (diastereoisomeric mixture)

- 15 1.06 g of pleuromutilin-22-O-tosylate dissolved in 1 ml of 2-butanone are slowly added to a solution of 466 mg of N-BOC-3-hydroxy-piperidin-4-thiol and 224 mg of potassium-tert. butylate in 20 ml of THF, the mixture obtained is stirred for 2 hours, the mixture obtained is distributed between brine and EtAc, extracted with 0.1N HCl, and the phases obtained are speareated. The organic phase obtained is dried, and the evaporation residue obtained is subjected to chromatography. A mixture of 14-O-[(3R*-Hydroxypiperidin-4-(R*)yl) -sulfanyl-acetyl]mutilin and 14-O-[(3S*-Hydroxypiperidin-4-(S*)yl) -sulfanyl-acetyl]mutilin is obtained which is treated with etheric HCl to obtain the corresponding hydrochloride. Characterisation data see in TABLE 5, Example 42.

Example I-E

2,2,4-Trideutero-14-O-[((3-(S*)-hydroxy-piperidine-4-(S*)-yl) sulfanyl)-acetyl]mutilin in the form of a deuterochloride

- A solution of 300 mg of the compound obtained in Example ID in 30ml dioxane with 5 ml of DCI (20% in D₂O) is kept for 6 days at 25°. From the mixture obtained solvent is evaporated and the concentration resiue is subjected to lyophilization. 2,2,4-Trideutero-14-O-[((3-(S*)-hydroxy-piperidine-4-(S*)-yl) sulfanyl)-acetyl]mutilin in the form of a deuterochloride is obtained. Characterisation data see TABLE 5, Example 41.

Example I-F

14-O-[3-(R*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(R*)-yl)sulfanyl)-acetyl]mutilin (a)

14-O-[3-(S*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(S*)-yl)sulfanyl)-acetyl]mutilin (b)

14-O-[3-(S*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(R*)-yl)sulfanyl)-acetyl]mutilin (c)

14-O-[3-(R*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(S*)-yl)sulfanyl)-acetyl]mutilin (d)

2.66 g of pleuromutilin-22-O-tosylate dissolved in 10ml THF are slowly added to a solution of

- 5 1.65 g of 3-(N-BOC-(R)-valyl-amino)-cyclohexane-(R/S)-thiol and 560 mg of potassium-tert. butylate in 25ml of THF, the mixture obtained is stirred for 2 hours and distributed between brine and EtAc. The mixture obtained is extracted with 0.1N HCl , the organic phase obtained is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography. Pure
- 10 (a) 14-O-[3-(R*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(R*)-yl)sulfanyl)-acetyl]mutilin
(b) 14-O-[3-(S*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(S*)-yl)sulfanyl)-acetyl]mutilin
(c) 14-O-[3-(S*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(R*)-yl)sulfanyl)-acetyl]mutilin, and
(d) 14-O-[3-(R*)-((N-BOC-(R)-Valyl-amino-cyclohexan-1-(S*)-yl)sulfanyl)-acetyl]mutilin is obtained. ¹H-NMR(d₆-DMSO):
- 15 (a): 6.5(d,1H,NH,J=8.1Hz), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5.2Hz,H₁₄), 3.4(m,1H, H₁₁), 3.55 (m,1H,CHN), 3.7 (m, α -valyl), 3.2 (m,2H,H₂₂), 2.7 (m,1H,SCH), 1.4 (s,9H, tert.butyl), 1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).
(b): 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5.2Hz,H₁₄), 3.4(m,1H,H₁₁), 3.55 (m,1H,CHN), 3.70 (m, α -valyl), 3.2 (m,2H,H₂₂), 2.7 (m,1H,SCH), 1.4 (s,9H,tert.butyl), 1.18,1.45(2xs, (CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).
- 20 (c): 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5.2Hz,H₁₄), 3.4(m,1H,H₁₁), 3.9 (m,1H,CHN), 3.75 (m, α -valyl), 3.2 (m,2H,H₂₂), 3.15 (m,1H,SCH), 1.4 (s,9H,tert.butyl), 1.18,1.45(2xs, (CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).
(d): 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5.2Hz,H₁₄), 3.4(m,1H,H₁₁), 3.9 (m,1H,CHN),
- 25 3.70 (m, α -valyl), 3.2 (m,2H,H₂₂), 3.15 (m,1H,SCH), 1.4 (s,9H,tert.butyl), 1.18,1.45(2xs, (CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).

Example I-G

14-O-[3-(R*)-((R)-Valyl-amino-cyclohexan-1-(R*)-yl)-sulfanyl]-acetyl]-mutilin and 14-O-[3-(S*)-((R)-Valyl-amino-cyclohexan-1-(S*)-yl)-sulfanyl]-acetyl]-mutilin in the form of a hydrochloride (mixture of trans-diastereoisomers)

620 mg of a 1:1 mixture of 14-O-[3-(R*)-((N-BOC-(R)-valyl-amino-cyclohexan-1-(R*)-yl)sulfanyl)-acetyl]mutilin and 14-O-[3-(S*)-((N-BOC-(R)-valyl-amino-cyclohexan-1-(S*)-yl sulfanyl)- acetyl]mutilin are dissolved in a mixture of 10 ml of dry etheric HCl and 10 ml of

CH_2Cl_2 . The mixture is stirred for 5 hours and a mixture of trans-diastereoisomers of 14-O-[3-(R*)-((R)-valyl-amino-cyclohexan-1-(R*)-yl)-sulfanyl]-acetyl]-mutilin or 14-O-[3-(S*)-((R)-valyl-amino-cyclohexan-1-(S*)-yl)-sulfanyl]-acetyl]-mutilin in the form of a hydrochloride is obtained and isolated. $^1\text{H-NMR}$ (d₆-DMSO,): Rotamer. 8.4 (m, 1H, C=ONH), 8.15 (b, 3H, NH₃⁺), 5 6.15, 5.1 (2xm, H₁₉, H₂₀, H₂₁), 5.52(d, 1H, J=5.2Hz, H₁₄), 3.95 (m1H, CHNH₃⁺, 3.4(m, 1H, H₁₁), 3.55 (m, α -valyl), 3.2-3.3 (m, 2H, H₂₂), 3.18 (m, 1H, SCH), 1.18, 1.45(2xs, (CH₃)₁₅, (CH₃)₁₈), 0.9 (m, 6H, CH(CH₃)₂), 0.75, 0.88 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=5.4Hz)

Example I-H

- 10 **14-O-[3-(R*)-((R)-Valyl-amino-cyclohexan-1-(S*)-yl)-sulfanyl]-acetyl]-mutilin and 14-O-[3-(S*)-((R)-Valyl-amino-cyclohexan-1-(R*)-yl)-sulfanyl]-acetyl]-mutilin in the form of a hydrochloride (mixture of cis-diastereoisomers)**
is obtained analagously to the method of Example I-G, but using a 1:1 mixture of 14-O-[3-(R*)-((N-BOC-(R)-valyl-amino-cyclohexan-1-(S*)-yl)sulfanyl)-acetyl]mutilin and 14-O-[3-(S*)-((N-BOC-(R)-valyl-amino-cyclohexan-1-(R*)-yl sulfanyl)-acetyl)mutilin as a starting material.
 $^1\text{H-NMR}$ (d₆-DMSO): Rotamers. 8.52 (m, 1H, C=ONH), 8.2 (b, 3H, NH₃⁺), 6.15, 5.1 (2xm, H₁₉, H₂₀, H₂₁), 5.52(d, 1H, J=5.2Hz, H₁₄), 3.58 (m1H, CHNH₃⁺, 3.4(m, 1H, H₁₁), 3.48 (m, α -valyl), 3.2-3.3 (m, 2H, H₂₂), 2.75 (m, 1H, SCH), 1.18, 1.45(2xs, (CH₃)₁₅, (CH₃)₁₈), 0.9 (m, 6H, CH(CH₃)₂), 0.75, 0.88 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=5.4Hz)

20

Example I-I

14-O-[((N-(R)-Valyl-azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the form of a hydrochloride

I-IA) 4-(R/S)-(2,4,6-Trimethyl-benzyl-sulfanyl)- azepan-2-one

- 25 A solution of 828 mg of 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexanone-oxime and 570 mg of toluenesulfonylchloride in 5 ml of pyridine is stirred at RT for 4 hours and additional 2 hours at 60°. The mixture obtained is distributed between diluted sulfuric acid (2 ml H₂SO₄ conc. in 15ml H₂O) and CH₂Cl₂, the organic phase obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography. 4-(R/S)-(2,4,6-
30 Trimethyl-benzyl-sulfanyl)- azepan-2-one is obtained. $^1\text{H-NMR}$ (d₆-DMSO): 7.5 (m, 1H, NHCO), 6.8 (s, 2H, arom.H), 3.75 (s, 2H, C₆H₅CH₂S-), 3.2 (m, 1H, CHN), 3.1(m, 3H, CH₂NH, CHS) AB-system: v_A= 2.72, v_B=2.65(2H, CH₂C=O, J=13.4Hz, J=4.5Hz) 2.13 2.15, 2.3(9H, 3xCH₃)

I-IB) 4-(R/S)-(2,4,6-Trimethyl-benzyl-sulfanyl)-azepane

3.3 g of 4-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-azepan-2-one are added to a mixture of 15 ml of a 1M-solution of LiAlH₃ and 50 ml THF are added. The mixture obtained is heated for 1 hour at 80°, poured into 200 ml of a 20% aqueous NH₄Cl-solution and the mixture obtained is extracted with EtAc. The organic phase obtained is dried and solvent is evaporated.

- 5 4-(R/S)-(2,4,6-Trimethyl-benzyl-sulfanyl)-azepane is obtained.

I-IC) N-BOC-(4-(R/S)-(2,4,6-Trimethyl-benzyl-sulfanyl))-azepane

A solution of 2.63 g of 4-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-azepane, 2.18 g of BOC-anhydride and 1 g of triethylamine in 100 ml of THF is stirred at 25° for 12 hours and from the mixture obtained solvent is evaporated. The evaporation residue obtained is distributed

- 10 between CH₂Cl₂ and 1M HCl. Solvent from the organic phase obtained is evaporated and the evaporation residue is subjected to chromatography. N-BOC-(4-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl))-azepane is obtained. ¹H-NMR(d₆-DMSO): 6.8 (s,2H,arom.H), 3.75

(s,2H,C₆H₅CH₂S-),3.2 -3.5(m,4H,CH₂NHCH₂), 2.9(m,1H,CHS), 2.13 2.15,2.3(9H, 3xCH₃)

I-IC) N-BOC-4-(R/S)-Azepan-thiol

- 15 is obtained analogously to the method of Example II-D, but using appropriate starting materials.

I-ID) 14-O-[((N-BOC-Azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin

A solution of 1.06 g of pleuromutilin-22-O-tosylate dissolved in 10 ml THF is slowly added to a solution of 420 mg of N-BOC-(4-(R/S)-azepane-thiol and 220 mg of potassium-tert.butylate

- 20 in 25 ml of THF and the mixture obtained is stirred for 2 hours. The mixture obtained is distributed between brine and EtAc, the mixture obtained is extracted with 0.1N HCl , the organic phase obtained is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography. 14-O-[((N-BOC-azepan-4-(R/S)-yl)-sulfanyl acetyl)-mutilin is obtained. ¹H-NMR(d₆-DMSO): 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5,2Hz,H₁₄), 4.52

25 (d,1H,OH,J=6.2Hz)3.4(t,1H,H₁₁,J=6.2Hz), 3.1-3.4 (m,6H,H₂₂,CH₂NCH₂), 2.9 (m,1H,SCH), 1.4 (s,9H,tert.butyl),1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

I-IE) 14-O-[((Azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the form of a hydrochloride -

- 400 mg of 14-O-[((N-BOC-azepan-4-(R/S)-yl)-sulfanyl-acetyl)-mutilin are dissolved in a mixture of 10 ml of dry etheric HCl and 10 ml of CH₂Cl₂. The mixture obtained is stirred 30 for 5 hours and 14-O-[((azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the form of a hydrochloride is isolated. Characterisation data see TABLE 1, Example 14.

I-IF) 14-O-[((N-(R)-Valyl-azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the form of a hydrochloride

A mixture of 245 mg 14-O-[((azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the form of a hydrochloride, 110 mg of BOC-R-valin, 95 mg of EDC and 100 mg of triethylamine in 10ml THF is stirred at RT for 2 hours. The mixture obtained is distributed between brine and EtAc, the organic phase obtained is dried, solvent is evaporated and the evaporation residue

5 obtained is subjected to chromatography.

14-O-[((N-BOC-(R)-Valyl-azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin-hydrochloride is obtained. The BOC-protecting group is cleaved by treatment with 5 ml of etheric HCl and 14-O-[((N-(R)-Valyl-azepan-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the form of a hydrochloride is obtained. Characterisation data see TABLE 1, Example 15.

10

Example I-J

14-O-[((Azepan-2-one-4-(R/S)-yl)-sulfanyl acetyl)]-mutilin

is obtained analogously to the method of Example IAB), starting from 4-(R/S)-mercapto-azepan-2-one. Characterisation data see TABLE 5, Example 43.

15

Example I-K

14-O-{[(3-Oxo-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin

A solution of 3.95 g of 14-mercapto-acetyl-mutilin in 5 ml of pyridine is treated with 0.81 g of cyclopent-2-enone and a catalytical amount of triethylamine. The mixture obtained is stirred

20 for 3 hours at room temperature, diluted with EtAc and extracted with 1N HCl and H₂O. The organic phase obtained is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography. 14-O-{[(3-oxo-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin is obtained. Characterisation data see in TABLE 5, Example 44.

25 **Example I-L**

14-O-{[(3-Hydroxyimino-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin (syn and anti forms)

3.88 g of 14-O-{[(3-oxo-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin are stirred overnight with 566 mg of hydroxylamine hydrochloride and 1.13 ml of triethylamine in 40 ml of DMF.

30 From the mixture obtained solvent is distilled off, the distillation residue obtained is taken up in EtAc and the mixture obtained is extracted with 0.1N HCl and brine. The organic phase obtained is dried and solvent is evaporated. A mixture of 14-O-{[(3-hydroxyimino-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin in the syn*- and in the anti*-form is obtained which mixture is either separated by chromatography to obtain the pure syn- and the pure anti-

forms, or is used in the form of the mixture obtained in further reaction steps.
Characterisation data see TABLE 3, Example 24.

Example I-M

- 5 **14-O-{{(3-(2-Diethylamino-ethoxyimino)-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin in the form of a hydrochloride}**
200 mg of 14-O-{{(3-hydroxyimino-cyclopentan-(R/S)-yl)-sulfanyl]-acetyl}-mutilin and 70 mg of diethylaminoethylchloride hydrochloride are stirred in 5 ml of CH₂Cl₂, 90 mg of potassium tert butoxide are added and stirring is continued for 2 days at RT. From the mixture obtained
- 10 solvent is evaporated, the evaporation residue is subjected to chromatography, the relevant chromatographic fractions obtained are distributed between Et₂O and 0.1N HCl and the aqueous layer is lyophilized. 14-O-{{(3-(2-diethylamino-ethoxyimino)-cyclopent-(R/S)-yl)-sulfanyl]-acetyl}-mutilin hydrochloride (syn/anti mixture) is obtained. Characterisation data see TABLE 3, Example 26.

15

Example I-N

14-O-[(2-(R*)-((R)-Valyl)-amino-cyclohexan-1-(R*)-yl)-sulfanyl acetyl]-mutilin-hydrochloride

I-NA) 14-O-[(2-(R*)-Aminocyclohexan-1-(R*)-yl)-sulfanyl acetyl]-mutilin

- 20 1.06 g of pleuromutilin-22-O-tosylate dissolved in 5ml of THF are slowly added to a solution of 334 mg of 2-(R*)-aminocyclohexan-(R*)-thiol in the form of a hydrochloride (see e.g. G.Kavadias and R.Droghini, Can.J.Chem. 1978,56, 2743) and 92 mg sodium in 50 ml of EtOH, the mixture obtained is stirred for 2 hours, distributed between brine and EtAc, extracted with 0.1N HCl and dried. From the mixture obtained solvent is evaporated and the
- 25 evaporation residue is subjected to chromatography. 14-O-[((2-(R*)-aminocyclohexan-1-(R*)-yl)-sulfanyl acetyl)-mutilin is obtained. ¹H-NMR(d₆-DMSO): 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5,2Hz,H₁₄), 2.45(m,1H,CHNH), 3.21 (s,2H,H₂₂), 3.4(d,1H, H₁₁,J=5Hz), 2.55(m,1H,CHS), 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.9 (m,6H,CH(CH₃)₂), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).

- 30 **I-NB) 14-O-[(2-(R*)-((R)-Valyl)-amino-cyclohexan-1-(R*)-yl)-sulfanyl acetyl]-mutilin in the form of a hydrochloride**

A mixture of 245 mg of 14-O-[((2-(R*)-aminocyclohexan-1-(R*)-yl)-sulfanyl acetyl)-mutilin, 110 mg of BOC-(R)-valin, 95 mg of EDC and 68mg of HOBT in 10 ml of THF is stirred at RT for 2 hours. The mixture obtained is distributed between brine and EtAc, the organic phase

obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography. 14-O-[((2-(R^{*})-(N-BOC-(R)-Valyl)-amino-cyclohexan-1-(R^{*})-yl)-sulfanyl acetyl)]-mutilin is obtained. The BOC-protecting group is cleaved by treatment with 5 ml of etheric HCl and 14-O-[(2-(R^{*})-((R)-valyl)-amino-cyclohexan-1-(R^{*})-yl)-sulfanyl acetyl)]-mutilin
5 in the form of a hydrochloride is obtained. ¹H-NMR(d₆-DMSO): Diastereoisomers):8.45(m, 1H, NHC=O), 8.1(b,3H,NH₃⁺), 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5.2Hz,H₁₄), 3.55 (m,1H, a-H-valyl), 3.60(m,1H,CHNH), 3.26-3.35 (m,2H,H₂₂), 3.4(m,1H, H₁₁), 4.5 (d,1H,OH, J=6.2Hz), 2.6,2.75(2xm,1H,CHS), 1.25 (b,3H,CH₃CS), 1.18,1.45(2xs,(CH₃)₁₅,(CH₃)₁₈), 0.9 (m,6H,CH(CH₃)₂), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz)

10

Example I-O

14-O-{{(3S,3aS,6S,6aR)-6-Amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin hydrochloride

I-OA) Toluene-4-sulfonic acid (3R, 3aS, 6R, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl ester

A solution of 5 g of (3R, 3aS, 6R, 6aR)-hexahydro-furo[3,2-b]furan-3,6-diol in 50 ml of pyridine is stirred for 16h with 7.8 g of toluenesulfonylchloride. From the mixture obtained solvent is distilled off and the distillation residue obtained is dissolved in EtAc and extracted with 1N HCl, saturated aqueous NaHCO₃-solution and H₂O. The organic layer obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography. Toluene-4-sulfonic acid (3R, 3aS, 6R, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl ester is obtained. ¹HNMR(DMSO-d₆): 7.8 (d,2H,Ar-H,J=8.6Hz), 7.5 (d,2H,Ar-H,J=8.6Hz), 4.8-4.9 (m,2H,H-3, 6-OH), 4.4 (dd,1H,H-3a,J=4.7 and 5.0Hz), 4.2 (dd,1H,H-6a,J=4.7 and 4.8Hz), 3.9-4.0 (m,1H,H-6), 3.7-3.8 (m,2H,H-2 and H-5), 3.6 (d,1H,H-2,J=9.3 and 7.1Hz), 3.2 – 25 3.4(m,1H,H-5), 2.4 (s, 3H, Ar-CH₃).

I-OB) (3R, 3aR, 6S, 6aR)-6-Azido-hexahydro-furo[3,2-b]furan-3-ol

A solution of 2.5 g of toluene-4-sulfonic acid (3R, 3aS, 6R, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl ester in 30 ml of DMF is heated with 0.8 g of sodium azide under reflux for 2 hours, solvent is distilled off and the distillation residue obtained is dissolved in EtAc and extracted with H₂O. The organic phase obtained is dried and solvent is evaporated. (3R, 3aR, 6S, 6aR)-6-azido-hexahydro-furo[3,2-b]furan-3-ol is obtained.

I-OC) {(3S, 3aR, 6R, 6aR)-6-Hydroxy-hexahydro-furo[3,2-b]furan-3-yl}-carbamic acid tert-butyl ester

To a solution of 1.5 g of (3R, 3aR, 6S, 6aR)-6-azido-hexahydro-furo[3,2-b]furan-3-ol in 25 ml of dioxane 75 mg of palladium on charcoal (10%) are added and the mixture obtained is subjected to hydrogenation. The mixture obtained is filtered and stirred overnight with 3.2 ml of ethyldiisopropylamine and 4.1 g of (BOC)₂O. From the mixture obtained solvent is evaporated. The evaporation residue obtained is dissolved in EtAc and extracted with saturated aqueous sodium NaHCO₃-solution, 1N HCl and brine. The organic phase obtained is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography. {(3S, 3aR, 6R, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl}-carbamic acid tert-butyl ester is obtained. ¹HNMR(DMSO-d₆): 7.1 (bs, 1H, NH), 4.8 (d, 1H, 6-OH, J=10Hz), 4.3 (dd, 1H, H-6a, J=4.6 and 4.3 Hz), 4.27 (d, 1H, H-3a, J=4.3Hz), 4.0-4.1 (m, 1H, H-6), 3.2-3.85 (m, 5H, 2xH-2, H-3, 2xH-5), 1.4 (s, 9H, tert.butyl).

I-OD) Toluene-4-sulfonic acid (3R, 3aS, 6S, 6aR)-6-tert-butoxycarbonylamino-hexahydro-furo[3,2-b]furan-3-yl ester

A solution of 700 mg of {(3S, 3aR, 6R, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl}-carbamic acid tert-butyl ester in 10 ml of pyridine is stirred for 16 hours with 785 mg of toluolsulfonylchloride, solvent is distilled off and the distillation residue is dissolved in EtAc and extracted with 1N HCl, saturated aqueous NaHCO₃-solution and H₂O. The organic layer obtained is dried and solvent is evaporated. Toluene-4-sulfonic acid (3R, 3aS, 6S, 6aR)-6-tert-butoxycarbonylamino-hexahydro-furo[3,2-b]furan-3-yl ester is obtained.

I-OE) 14-O-[(3S,3aS,6S,6aR)-6-tert-Butoxycarbonylamino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl-mutilin

267 mg of potassium tert.butoxide are added to a solution of 950 mg of toluene-4-sulfonic acid (3R, 3aS, 6S, 6aR)-6-tert-butoxycarbonylamino-hexahydro-furo[3,2-b]furan-3-yl ester and 1032 mg of 14-mercapto-acetyl-mutilin in 20 ml of DMSO. The mixture obtained is stirred at 70° for 1 hour and distributed between EtAc and brine. The organic phase obtained is washed with H₂O, dried and solvent is evaporated. The evaporation residue obtained is subjected to chromatography. 14-O-[(3S,3aS,6S,6aR)-6-tert-butoxycarbonyl-amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl-mutilin is obtained. ¹HNMR(DMSO-d₆): 7.1 (bs, 1H, NH), 6.1, 5.05, 5.0 (3xm, H₁₉, H₂₀, H₂₁), 5.55 (d, 1H, H₁₄, J=8.2Hz), 4.5 (m, 2H, H₁₁-OH, H-3a'), 4.4 (d, 1H, H-6a', J=4Hz), 3.3-4.0 (m, 9H, H-2', H-3', H-5', H-6', H₁₁, H₂₂), 1.36 (s, 9H, tert-butyl), 1.34, 1.05 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.8, 0.62 (2xd (CH₃)₁₆, (CH₃)₁₇, J=6.8Hz).

I-OF) 14-O-[(3S,3aS,6S,6aR)-6-Amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl-mutilin

950 mg of 14-O-{[(3S,3aS,6S,6aR)-6-tert-butoxycarbonylamino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin are dissolved in 20 ml of CH₂Cl₂ and the mixture obtained is stirred for 2 hours with 3 ml of TFA. The mixture obtained is diluted with EtAc and extracted with saturated aqueous NaHCO₃-solution. The organic phase obtained is dried and solvent is evaporated. 14-O-{[(3S,3aS,6S,6aR)-6-amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin is obtained.

I-OG) 14-O-{[(3S,3aS,6S,6aR)-6-Amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin in the form of a hydrochloride

180 mg of 14-O-{[(3S,3aS,6S,6aR)-6-amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-

10 mutilin are distributed between diethylether and 0.1N HCl. The aqueous layer obtained is lyophilized. 14-O-{[(3S,3aS,6S,6aR)-6-Amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin in the form of a hydrochloride is obtained. Characterisation data see in TABLE 4, Example 36a above.

15 Example I-P

14-O-{[(3S,3aS,6S,6aR)-6-((R)-Amino-3-methyl-butyrylarnino)-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin in the form of a hydrochloride

A solution of 400 mg of 14-O-{[(3S,3aS,6S,6aR)-6-amino-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin in 20 ml of CH₂Cl₂ is treated with 128 mg of N-Boc-(R)-valine, 147

20 mg of EDC, 104 mg of HOBT and the mixture obtained is stirred overnight at RT. The mixture obtained is diluted with CH₂Cl₂, extracted with H₂O, dried and solvent is evaporated. The evaporation residue obtained is subjected to chromatography on silica gel, relevant chromatographic fractions obtained are treated again with TFA in CH₂Cl₂, solvent is evaporated, the evaporation residue obtained is distributed between Et₂O and 0.1N HCl and 25 the aqueous layer obtained is lyophilized. 14-O-{[(3S,3aS,6S,6aR)-6-((R)-2-amino-3-methylbutyrylarnino)-hexahydro-furo[3,2-b]furan-3-ylsulfanyl]-acetyl}-mutilin in the form of a hydrochloride is obtained. Characterisation data see in TABLE 5, Example 38a.

Example I-Q

30 14-O-{[(3-(R/S)-Amino-cyclohexan-1-(R/S)-yl)-sulfanyl acetyl]}-mutilin in the form of a hydrochloride

10.6g of pleuromutilin-22-O-tosylate dissolved in 10 ml of THF are slowly added to a solution of 5.2 g of N-BOC-3-(R/S)-mercapto-cyclohexylamin and 2.74 g of potassium-tert.butylate in 250 ml of THF. The mixture obtained is stirred for 2 hours, distributed between brine and

EtAc, and extracted with 0.1N HCl. The organic phase obtained is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography. 14-O-[((N-BOC-3(R/S)-amino-cyclohexan-1-(R/S)-yl)-sulfanyl acetyl)]-mutilin is obtained and is converted into 14-O-[((3-(R/S)-Amino-cyclohexan-1-(R/S)-yl)-sulfanyl acetyl)]-mutilin in the

5 form of a hydrochloride by treatment with etheric HCl.

¹H-NMR(d₆-DMSO): 8.0 (b, 3H, NH₃⁺), 6.15, 5.1 (2xm, H₁₉, H₂₀, H₂₁), 5.52(d, 1H, J=5.2Hz, H₁₄), 3.4(m, 1H, H₁₁), 3.3 (m, 2H, H₂₂), 2.9 (m, 1H, NCH), 2.7(m, 1H, CHS), 1.18, 1.45 (2xs, (CH₃)₁₅, (CH₃)₁₈), 0.75, 0.88 (2xd, (CH₃)₁₆, (CH₃)₁₇, J=5.4Hz)

10 **II. Preparation of intermediates (starting materials) for the preparation of a (novel) pleuromutilin of the present invention**

Example II-A 14-Mercapto-acetyl-mutilin

II-AA) 14-O-[(Carbamimidoylsulfanyl)acetyl]mutilin-tosylate

15 A solution of 15.2 g of thiourea and 106.4 g of pleuromutilin-22-O-tosylate in 250 ml of acetone is heated under reflux for 1.5 hours, solvent is removed and 100 ml of hexane are added. A precipitate forms, is filtrated off and dried.

14-O-[(carbamimidoylsulfanyl)acetyl]mutilin-tosylate is obtained.

II-AB) 14-Mercapto-acetyl-mutilin

20 A solution of 4.7 g of Na₂S₂O₅ in 25 ml of H₂O is added to a solution of 12.2 g of 14-O-[(carbamimidoylsulfanyl)acetyl]mutilin-tosylate in a mixture of 20 ml of EtOH and 35 ml of H₂O (warmed to ca. 90°). 100 ml of CCl₄ are added to the reaction mixture obtained and the mixture obtained is heated under reflux for ca. 2 hours. The two-phase system obtained is separated, the organic phase is dried and solvent is evaporated. 14-mercaptop-acetyl-mutilin
25 is obtained.

Example II-B N-BOC-3(R)-methylsulfonyloxy-piperidine

II-BA) N-BOC-3(R)-Hydroxy-piperidine

30 A suspension of 3.48 g of 3-(R)-hydroxypiperidine, 8.72 g of di-tert.butyl-dicarbonat and 4 g of N-methyl-morpholine in 70 ml of dioxane is stirred for 18 hours at RT. From the mixture obtained solvent is evaporated and the evaporation residue obtained is dissolved in CH₂Cl₂ and extracted with 1N HCl. The organic phase obtained is dried and solvent is evaporated. N-BOC-3(R)-hydroxy-piperidine is obtained.

II-BB) N-BOC-3(R)-methylsulfonyloxy-piperidine

A solution of 5.08 g of N-BOC-3(R)-hydroxy-piperidine and 8.7 g of methanesulfonic acid anhydride in 100 ml pyridine is stirred at RT for 22 hours, pyridine is distilled off, the distillation residue is dissolved in CH₂Cl₂, the mixture obtained is extracted with 1N HCl, the organic phase obtained is dried, solvent is evaporated and the evaporation residue obtained

5 is subjected to chromatography. N-BOC-3(R)-methylsulfonyloxy-piperidine is obtained.

¹H-NMR(CDCl₃): 4.7(m,1H,CHOSO₂CH₃), 3.2-3.6(m,4H,CHN), 3.0(s,3H,CH₃SO₂), 1.4(m, 9H,tert.butyl).

Example II-C N-BOC-Piperidine-3(S)-thiol

10 II-CA) N-BOC-3-(S)-Thioacetoxy-piperidine

A solution of 2.2 g of N-BOC-3-(R)-hydroxy-piperidine in 10 ml of THF is added under argon and 1 ml of thiolacetic acid to a solution of 3.4 g of triphenylphosphine and 2.65 ml of azadicarbonic acid-isopropylate in 10 ml of THF. The mixture obtained is kept for 18 hours at 70°, solvent is evaporated and the evaporation residue obtained is subjected to

15 chromatography. N-BOC-3-(S)-thioacetoxy-piperidine is obtained. ¹H-NMR (CDCl₃): 3.78 (dd,1H,NCH₂CHS, J=3.1Hz, J=13.3Hz), 3.5-3.6 (m,2H, CHSC=O, NCH₂CH₂), 2.32(s,3H,SC=OCH₃), 1.46(s,9H, tert.butyl)

II-CB) N-BOC-Piperidine-3(S)-thiol

To a solution of 259 mg of N-BOC-3-(S)-thioacetoxy-piperidine in 10 ml of MeOH a solution 20 of 262 mg of NaSCH₃ in 5 ml of MeOH is added and the mixture obtained is stirred for 2 hours, solvent is evaporated and the evaporation residue obtained is distributed between EtAc and aqueous HCl. Solvent from the organic phase obtained is evaporated.

N-BOC-piperidine-3(S)-thiol is obtained. ¹H-NMR(d₆-DMSO): 2.6 (d,1H,SH, J=7.2Hz), , 2.9-2.7 (m,3H, NCH₂CHS), 1.35 (b,9H,tert.butyl). MS(ESI) 457 (2M+Na).

25

Example II-D 3-(N-BOC-(R)-Valyl-amino)-cyclohexane-(R/S)-thiol

II-DA) 3-(R/S)-(2,4,6-Trimethyl-benzyl-sulfanyl)-cyclohexanone

A solution of 3.32 g of 2,4,6-trimethyl-benzylmercaptane and 3.84 g of cyclohexen-3-one in 30 ml of pyridine is heated at 40° for 3 hours. The mixture obtained is poured into 200 ml of 30 1M HCl and the mixture obtained is extracted with CH₂Cl₂. The organic phase obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography on silica gel. 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexanone is obtained.

¹H-NMR(d₆-DMSO): 6.8 (s,2H,arom.H), 3.8 (s,2H,C₆H₅CH₂S-), 3.3 (m,1H,CHS), 3.18 (dd,1H, CHC=NOH, J= 4Hz,13.9Hz), 2.65-2.8, 2.44-2.49(2xm,4H,CH₂C=OCH₂), 2.15,2.3(9H,3xCH₃).

II-DB) 3-(R/S)-(2,4,6-Trimethyl-benzyl-sulfanyl)- cyclohexanone-oxime (syn and anti-forms)

A solution of 5.24 g of 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexanone, 1.38 g of hydroxylamine in the form of a hydrochloride and 2 g of triethylamine in 50 ml of MeOH is stirred at 25° for 12 hours, the mixture obtained is poured into 200 ml of brine and the

5 mixture obtained is extracted with CH₂Cl₂. The organic phase obtained is dried and solvent is evaporated. A mixture of the syn- and anti forms of 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexanone-oxime is obtained which is subjected to chromatography. Pure syn- and pure anti-3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexanone-oxime is obtained.

10 ¹H-NMR(d₆-DMSO) of the syn-form: 10.3 (s,1H,OH), 6.8 (s,2H,arom.H), 3.75 (s,2H, C₆H₅CH₂S-), 2.88 (m,1H,CHS), 3.18 (dd,1H,CHC=NOH, J= 4Hz,13.9Hz), 2.13 (dd,1H, CHC=NOH, J= 5.2Hz,13.9Hz), 2.15,2.3(9H, 3xCH₃).

15 ¹H-NMR(d₆-DMSO) of the anti-form: 10.3 (s,1H,OH), 6.8 (s,2H,arom.H), 3.75 (s,2H, C₆H₅CH₂S-), 2.92(m,1H,CHS), 2.58 (dd,1H,CHC=NOH, J= 4Hz,13.9Hz), 2.15 (dd,1H, CHC=NOH, J= 4.2Hz,13.6Hz), 2.15,2.3(9H, 3xCH₃).

15 II-DC) 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexyl-(R/S)-amine

2.7 g of 3-(R/S)-(2,4,6-Trimethyl-benzyl-sulfanyl)-cyclohexanone-oxime are added to a mixture of 20 ml of a 1M-solution of LiAlH₄ and 15 ml of dioxane, the mixture obtained is heated for 1 hour at 80° and the mixture obtained is poured into 200 ml of a 20% aqueous NH₄Cl-solution. The mixture obtained is extracted with EtAc, the organic phase obtained is dried and solvent is evaporated. 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexyl-(R/S)-amine is obtained.

20 II-DC) 3-(N-BOC-(R)-Valyl-amino)-cyclohexan-1-(R/S)-yl- sulfanylmethyl-(2,4,6-trimethyl-benzol)

25 A mixture of 1.05 g of 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexyl-(R/S)-amine, 870 mg of BOC-R-valine, 760 mg of EDC and 404 mg of triethylamine in 20ml THF is stirred at RT for 2 hours. The mixture obtained is distributed between brine and EtAc, the organic phase obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography. 3-(N-BOC-(R)-valyl-amino)-cyclohexan-1-(R/S)-yl-sulfanylmethyl-(2,4,6-trimethyl-benzol) is obtained. ¹H-NMR(d₆-DMSO): Rotamers, 7.78, 7.3, 6.52 (3xd,2H,NH), 30 J=7.9Hz), 6.8, 6.82 (2xs,2H, arom.H), 6.55 (m,1H,NHC=O), 3.7 (m,1H,a-H-valyl), 3.6 (m,1H,NHCH), 2.75, 3.0 (2xm,1H, CHS), 1.39(s,9H,tert.butyl)

II-DD) 3-(N-BOC-(R)-Valyl-amino)-cyclohexane-(R/S)-thiol

10 ml ammonia are condensed at -70° within a solution of 600 mg of 3-(N-BOC-(R)-valyl-amino)-cyclohexan-1-(R/S)-yl- sulfanylmethyl-2,4,6-trimethyl-benzol in 15 ml of THF and

sodium is added in portions until the solution remains deep blue. Solid NH₄Cl is added to the mixture obtained and the mixture obtained is allowed to warm up to RT, is flushed with nitrogen, the solid residue obtained is filtered off, the filtrate obtained is concentrated and subjected to chromatography on silica gel. 3-(N-BOC-(R)-Valyl-amino)-cyclohexane-(R/S)-thiol is obtained. ¹H-NMR(d₆-DMSO): Rotamer, 7.75 (m,1H,NHC=O), 6.55 (m,1H,NHC=O), 2.75 (m,1H,CHS), 2.58(d,1H,SH,J=6.6Hz), 1.39(s,9H,tert.butyl)

Analogously to the method as set out in Example II-D but using appropriate starting materials the following compounds are obtained:

- 10 **Example II-D-1 N-BOC-3-(R/S)-mercapto-cyclohexylamin**
 Example II-D-2 4-(R/S)-Mercapto-azepan-2-one
 from 4-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-azepan-2-one. ¹H-NMR(d₆-DMSO): 6.15, 5.1 (2xm,H₁₉,H₂₀,H₂₁), 5.52(d,1H,J=5.2Hz,H₁₄), 3.4(m,1H,H₁₁), 3.3 (m,2H,H₂₂), 2.99-15 3.12(b,2H,CH₂N), 3.18(m,1H,SCH), 2.7 (m,1H,C=OCH), 2.67(d,1H,SH,J=5.5Hz), 2.58(d,1H,C=OCH,J=13.5Hz), 1.18,1.45 (2xs,(CH₃)₁₅,(CH₃)₁₈), 0.75,0.88 (2xd,(CH₃)₁₆,(CH₃)₁₇,J=5.4Hz).

- 20 **Example II-E N-BOC-3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)- cyclohexyl-(R/S)-amine**
 A solution of 11 g of 3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)-cyclohexylamine, 9.15 g of BOC-anhydride and 4.2 g of triethylamine in 100 ml of THF is stirred at 25° for 12 hours, solvent is evaporated and the concentrated residue is distributed between CH₂Cl₂ and 1M HCl. From the organic phase obtained solvent is evaporated and the evaporation residue is subjected to chromatography. N-BOC-3-(R/S)-(2,4,6-trimethyl-benzyl-sulfanyl)- cyclohexyl-(R/S)-amine is obtained. ¹H-NMR(d₆-DMSO): 6.81,(s,1H,NHCO), 6.8 (s,2H, arom.H), 3.75 (s,2H,C₆H₅CH₂S-),3.2 (m,1H,CHN), 2.70 (m,1H,CHS), 2.13 2.15,2.3(9H, 25 3xCH₃),1.4(s,9H,tert.butyl)

- 30 **Example II-F Toluene-4-sulfonic acid (3S, 3aS, 6R, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl ester and Toluene-4-sulfonic acid (3R, 3aS, 6S, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl ester**

A solution of 8.76 g of (3S, 3aS, 6R, 6aR)-hexahydro-furo[3,2-b]furan-3,6-diol in 80 ml of pyridine is stirred for 16 hours with 13.7 g of toluenesulfonylchloride, solvent is distilled off and the distillation residue is dissolved in EtAc and extracted with 1N HCl, saturated

aqueous NaHCO₃-solution and H₂O. The organic layer obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography. Toluene-4-sulfonic acid (3S, 3aS, 6R, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl ester (a) and toluene-4-sulfonic acid (3R, 3aS, 6S, 6aR)-6-hydroxy-hexahydro-furo[3,2-b]furan-3-yl ester (b) are obtained.

5 ¹HNMR(DMSO-d₆) of form (a): 7.8 (d,2H,Ar-H,J=8.2Hz), 7.5 (d,2H,Ar-H,J=8.6Hz), 4.95 (d,1H,6-OH), 4.8 (m, 1H, H-3), 4.42 (dd,1H,H-6a,J=4.6 and 4.8Hz), 4.38 (d,1H,H-3a,J=4.6), 4.08 (m,1H,H-6), 3.8 (m,2H,2xH-2), 3.7, 3.25 (2xdd, 2H, 2xH-5), 2.4 (s, 3H, Ar-CH₃). ¹HNMR(DMSO-d₆) of form (b): 7.8 (d,2H,Ar-H,J=8.6Hz), 7.5 (d,2H,Ar-H,J=8.6Hz), 5.15 (d, 6-OH, J=3.5), 4.9 (m,1H,H-3), 4.45 (dd,1H,H-3a,J=4.3 and 4.8Hz), 4.2 (d,1H,H-6a,J=4.3), 4.0 (m,1H,H-6), 3.7 (m,3H,H-2 and 2xH-5), 3.5 (dd,1H,H-2,J=9.5 and 6.3Hz), 2.4 (s, 3H, Ar-CH₃).

10

Example II-G

N-BOC-4-Hydroxy-piperidin-3-thiol, N-BOC-3-Hydroxy-piperidin-4-thiol

15 A solution of 1 g of N-BOC-3,4-epoxy-piperidin, 1.9 g of triphenylsilylmercaptane and 0.7 ml of triethylamine in 12.5 ml of THF is stirred for 24 hours at 70°, and 1.7g of TBAF and 0.9 ml acetic acid are added. The mixture obtained is stirred for 1 hour and distributed between brine and EtAc. The organic phase is dried, solvent is evaporated and the evaporation residue obtained is subjected to chromatography on silica gel. (a): N-BOC-4-Hydroxy-piperidin-3-thiol, and (b): N-BOC-3-hydroxy-piperidin-4-thiol are obtained.

20

¹H-NMR (CDCl₃) of (a): 4.45, 4.12, 2.8 (3xm,3H,CH₂NCH), 3.31 (dt, 1H, CHO, J=4.3Hz,J=10Hz), 2.65,2.6(2xm,2H,CHN,CHS), 1.5(s,9H,tert.butyl).

¹H-NMR (CDCl₃) of (b): 4.25, 3.45 2.7, (3xm,3H,CH₂NCH), 3.2 (m,1H,CHO), 2.55(m,2H, NCH,CHS), 1.5(s,9H,tert.butyl).

25

Test Examples

Example A

Determination of *Mycobacterium tuberculosis* strain resistance

Activity of the known compounds Isoniacid, Rifampicin and Streptomycin against

30 *M.tuberculosis* strains 1 to 14 as set out in TABLE A is determined in the Agar Dilution Test according to the method as described in the General Procedure. The MIC is determined after 3, 4 and 5 weeks. The strains 1 to 7 tested were found to be either sensible (S) or resistant (R) against Isoniacid, Rifampicin and/or Streptomycin. Results are as set out in TABLE A below:

TABLE A

<i>M.tuberculosis</i>	Isoniacid	Rifampicin	Streptomycin
Strain 1	S	S	S
Strain 2	S	S	S
Strain 3	R	R	S
Strain 4	R	R	R
Strain 5	R	R	S
Strain 6	S	S	S
Strain 7	R	S	R
Strain 8	S	R	S
Strain 9	R	S	R
Strain 10	S	S	S
Strain 11	S	S	S
Strain 12	S	S	S
Strain 13	S	S	S
Strain 14	S	S	S
Strain 15	S	S	S

Strain 15 is the labor strain 137kV. Resistant and sensible strains are isolated from patients

- 5 with known sensibilities/resistance. A strain is designated as resistant if its MIC in testing according to the General Test Procedure after 3 to 5 weeks is higher than 20 µg/ml.

Example B

- Activity of TEST COMPOUNDS (TCs) against *M.tuberculosis* strains 1 to 5 and 7 as set out
10 in TABLE A is determined in the Agar Dilution Test under conditions as in Example A in different agar concentrations of the TEST COMPOUNDS.

The MIC is determined after 3, 4 and 5 weeks.

Activity of the following TEST COMPOUNDS (TC) is tested:

- 15 A compound of formula I-Tiamulin: TC-1
A compound of formula I-Valnemulin: TC-2
A compound of formula I-PREF1: TC-3
A compound of formula I-PREF2: TC-4

- A compound of formula I-PREF3: TC-5
A compound of formula I-PREF4: TC-6
A compound of formula I-PREF5: TC-7
A compound of formula I-PREF6: TC-8
5 A compound of formula I-PREF7: TC-9
A compound of formula I-PREF8: TC-10

Test results are as set out in TABLE B below are obtained:

10

TABLE B

TC/week	MIC ($\mu\text{g/ml}$) against <i>Mycobacterium tuberculosis</i> of strain number					
	1	2	3	4	6	7
TC-1/3	5	5	5	5	10	10
TC-1/4	5	5	5	10	10	20
TC-1/5	5	5	5	10	10	20
TC-2/3	0.5	1	1	5	5	5
TC-2/4	0.5	5	1	5	5	5
TC-2/5	0.5	5	5	5	5	10
TC-3/3	1	5	5	1	5	20
TC-3/4	1	5	5	5	10	20
TC-3/5	1	5	5	10	10	20
TC-4/3	0.5	5	1	1	5	5
TC-4/4	1	5	1	5	5	5
TC-4/5	1	5	5	5	5	5
TC-5/3	1	5	5	5	5	5
TC-5/4	5	5	5	5	10	10
TC-5/5	5	5	5	10	10	10

Example C

Is carried out according to the method of Example B. Test results obtained are as set out in TABLE C and in TABLE D and in TABLE E:

15

TABLE C

TC/week	MIC ($\mu\text{g/ml}$) against <i>Mycobacterium tuberculosis</i> of strain number							
	1	2	3	4	5	6	7	8
TC-2/3	0.5	4	2	8	2	4	4	4
TC-2/4*)	0.5	4	2	8	4	4	8	8
TC-4/3	1	4	1	4	2	4	2	2
TC-4/4	2	4	1	4	2	4	4	2
TC-4/5	2	4	1	4	2	4	4	4

*) Tested after 31 days and thus no further testing after 5 weeks.

5

TABLE D

TC/week	MIC ($\mu\text{g/ml}$) against <i>Mycobacterium tuberculosis</i> of strain number					
	10	11	12	13	14	15
TC-2/3	4	2	4	4	4	2
TC-2/4*)	4	4	4	8	4	4
TC-4/3	2	2	2	2	4	2
TC-4/4	2	2	2	2	4	2
TC-4/5	4	2	4	4	4	4

*) Tested after 31 days and thus no further testing after 5 weeks.

TABLE E

TC/week	MIC ($\mu\text{g/ml}$) against <i>Mycobacterium tuberculosis</i> of strain number		
	1	12	15
TC-6/2	1	1	0.5
TC-7/1	2	32	32
TC-8/1	2	32	32
TC-9/1	8	32	32
TC-10/2	2	16	4

In TABLES B to E in the column "TC/week" the term "TC-number" indicates the TEST COMPOUND as defined above, e.g. TC-1 indicates a compound of formula I-Tiamulin; and "/week" indicates the MIC-determination point (in weeks from inoculation) in the testing of such TEST COMPOUND. "TC-1/3" for example indicates that the MIC of a compound of formula I-Tiamulin was determined after 3 weeks from inoculation.

10

MIC is the minimum inhibition concentration as defined above. The strain numbers 1 to 4 and 6 to 7 indicated in TABLE B, the strain numbers 1 to 9 indicated in TABLE C and the strain numbers 10 to 15 indicated in TABLE D, and the strain numbers 1, 12 and 15 indicated in TABLE E refer to the corresponding *Mycobacterium tuberculosis* strains of

5 Example A.


Furthermore compounds of formula I_{EX} and compounds of formula I'_{EX} wherein R_{EX} is as defined in TABLE 6 below have also proved to show activity against strains 1, 12 and 15 (all compounds tested in the form of hydrochlorides):

TABLE 6

	R _{EX}	R _{EX}	R _{EX}
Compound I _{EX}			
Compound I' _{EX}			
Compound I _{EX}			
Compound I' _{EX}			
Compound I' _{EX}			


Patent Claims

1. Use of a pleuromutilin in the preparation of a medicament for the treatment of diseases caused by *Mycobacterium*.
- 5 2. A method of treating diseases mediated by *Mycobacterium*, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.
- 10 3. Use according to claim 1 or a method according to claim 2 wherein *Mycobacterium* is *Mycobacterium tuberculosis*.
4. Use or a method according to any one of the preceding claims wherein a pleuromutilin is a compound comprising the basic structural elements as set out in formula




15 wherein R is vinyl or ethyl and the dotted line is a bond or is no bond.


5. Use or a method according to claim 4 wherein a pleuromutilin is selected from the group consisting of
- 20 - a compound of formula




- a compound of formula



- a compound of formula




- a compound of formula




5

- a compound of formula




- a compound of formula



I-PREF4


- a compound of formula



I-PREF5


5

- a compound of formula



I-PREF6


- a compound of formula



I-PREF7

and

- a compound of



- 5 6. A compound selected from the group consisting of compounds of formulae as set out in
TABLE 1:

TABLE 1






TABLE 1



7. A compound of formula



wherein


- the dotted line is a bond (double bond between positions a=b), R_{1A} is hydrogen and R_{2A} is not present,

or

- 5 - the dotted line is no bond (single bond between positions a-b) and R_{1A} and R_{2A} independently of each other are hydrogen, halogen or deuterium,
R_{3A} is (C₁₋₆)alkyl,
R_{4A} is hydrogen, (C₁₋₆)alkyl, a group -C(=NH)-NH₂, or the residue of an amino acid,
R_{5A} is hydrogen, or
10 R_{4A} and R_{5A} together are a group =CH-NH₂,
R_{6A} is hydrogen or deuterium, and
m_A is 0, 1, 2, 3, 4, or 5.

- 15 8. A 14-O-(oximino-(C₃₋₈)cycloalkyl-sulfanyl)methylcarbonyl)-pleuromutilin and a 14-O-(hydrazono-(C₃₋₈)cycloalkyl-sulfanyl)methylcarbonyl)-pleuromutilin.

9. A compound of formula



wherein

- 20 R_{1B} has the meaning of R_{1A} as defined in claim 7,
R_{2B} has the meaning of R_{2A} as defined in claim 7,
R_{10B} has the meaning of R_{6A} as defined in claim 7,
the dotted line has the meaning as defined in claim 7,
m_B has the meaning of m_A as defined above,
25 R_{3B} is hydrogen or (C₁₋₆)alkyl,
X_B is -O-R_{4B} or -NR_{5B}R_{6B},
R_{4B} is hydrogen or (C₁₋₆)alkyl, optionally substituted by a group -NR_{7B}R_{8B},
R_{5B} and R_{6B} independently of each other are (C₁₋₄)alkyl,


R_{7B} and R_{8B} independently of each other are (C₁₋₄)alkyl, or

R_{7B} and R_{8B} together with the nitrogen atom to which they are attached form aliphatic heterocyclil, having 5 to 8 ring members, and

R_{9B} is hydrogen or (C₁₋₄)alkyl.

5

10. A compound of formula



wherein

R_{1C} has the meaning of R_{1A} as defined in claim 7,

10 R_{2C} has the meaning of R_{2A} as defined in claim 7,


the dotted line has the meaning as defined in claim 7,

R_{4C} has the meaning of R_{6A} as defined in claim 7, and

R_{3C} is amino, (C₁₋₄)alkylamino, di(C₁₋₄)alkylamino, the residue of an amino acid, hydroxy, or (C₁₋₄)alkoxy.

15

11. A compound of formula



wherein

R_{1D} has the meaning of R_{1A} as defined in claim 7,

20 R_{2D} has the meaning of R_{2A} as defined in claim 7,

R_{4D} has the meaning of R_{6A} as defined in claim 7,

the dotted line has the meaning as defined in claim 7, and

R_{3D} is aliphatic heterocycl of 4 to 8 ring members, and comprising one nitrogen atom as the heteroatom, or (C₄₋₈)cycloalkyl, which heterocycl or cycloalkyl is substituted by hydroxy or oxo.

- 5 12. A compound of any one of claims 7 to 11 in the form of a salt.
13. A compound of any one of claims 7 to 12 for use as a pharmaceutical.
14. A pharmaceutical composition comprising a compound of any one of claims 7 to 12 in
10 association with at least one pharmaceutical excipient.
15. A pharmaceutical composition according to claim 13, further comprising another
 pharmaceutically active agent.
16. A pharmaceutical composition comprising a pleuromutilin in association with at least one
 pharmaceutical excipient, and further comprising another pharmaceutically active agent
 useful in the treatment of Mycobacterium infections.
17. A compound of any one of claims 7 to 12, or a pharmaceutical composition of any one
20 of claims 14 or 15 for use in the preparation of a medicament for the treatment of
 microbial diseases.
- 18. A method of treatment of microbial diseases, which method comprises administering to
 a subject in need of such treatment an effective amount of a compound of any one of
25 claims 7 to 12 or a pharmaceutical composition of any one of claims 14 or 15.

Abstract

5

A method of preventing or treating diseases caused by Mycobacterium, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.